[68] Peters BM, Jabra-Rizk MA, Scheper MA, Leid JG, Costerton JW, Shirtliff ME. Microbial interactions and differential protein expression in *Staphylococcus aureus*-*Candida albicans* dual-species biofilms. FEMS Immunology and Medical Microbiology. 2010;**59**(3):493-503

[69] Lin YJ, Alsad L, Vogel F, Koppar S, Nevarez L, Auguste F, et al. Interactions between *Candida albicans* and *Staphylococcus aureus* within mixed species biofilms. Bios. 2013;

[70] Harriott MM, Noverr MC. Ability of *Candida albicans* mutants to induce *Staphylococcus aureus* vancomycin resistance during polymicrobial biofilm formation. Antimicrobial

[71] Pammi M, Liang R, Hicks JM, Barrish J, Versalovic J. Farnesol decreases biofilms of *staphylococcus epidermidis* and exhibits synergy with nafcillin and vancomycin. Pediatric

[72] Rajendran R, Sherry L, Lappin DF, Nile CJ, Smith K, Williams C, et al. Extracellular DNA release confers heterogeneity in *Candida albicans* biofilm formation. BMC Microbiology.

[73] Sapaar B, Nur A, Hirota K, Yumoto H, Murakami K, Amoh T, et al. Effects of extracellular DNA from *Candida albicans* and pneumonia-related pathogens on *Candida* biofilm formation and hyphal transformation. Journal of Applied Microbiology. 2014;**116**(6):1531-1542

[74] Jabra-Rizk MA, Falkler WA, Merz WG, Kelley JI, Baqui AAMA, Meiller TF. Coaggregation of *Candida dubliniensis* with *Fusobacterium nucleatum*. Journal of Clinical Microbiology.

patients on cancer therapy. Microbial Pathogenesis. 2018;**123**(July):190-195

plaque biofilms in vivo. Infection and Immunity. 2014;**82**(5):1968-1981

2011;**77**(18):6357-6367

136 Candida Albicans

**84**(1):30-39

2014;**14**:303

1999;**37**(5):1464-1468

Microbial Pathogenesis. 2014;**73**:7-12

cavity. Archives of Oral Biology. 2015;**60**(9):1410-1415

tissue. Microbiology. 2015;**161**(Pt 1):168-181

Agents and Chemotherapy. 2010;**54**(9):3746-3755

Research. 2011;**70**(6):578-583

[90] Garcia-Perez JE, Mathé L, Humblet-Baron S, Braem A, Lagrou K, Van Dijck P, et al. A framework for understanding the evasion of host immunity by *Candida* biofilms. Frontiers in Immunology. 2018;**9**:538

[103] Nobile CJ, Johnson AD. *Candida albicans* biofilms and human disease. Annual Review

Interactions of *Candida albicans* Cells with Aerobic and Anaerobic Bacteria during Formation…

http://dx.doi.org/10.5772/intechopen.81537

[104] Peleg AY, Hogan DA, Mylonakis E. Medically important bacterial–fungal interactions.

[105] Roux D, Gaudry S, Dreyfuss D, El-Benna J, de Prost N, Denamur E, et al. *Candida albicans* impairs macrophage function and facilitates *Pseudomonas aeruginosa* pneumonia in

[106] Lopez-Medina E, Fan D, Coughlin LA, Ho EX, Lamont IL, Reimmann C, et al. *Candida albicans* inhibits *Pseudomonas aeruginosa* virulence through suppression of pyochelin and pyoverdine Biosynthesis. Hogan DA, editor. PLoS Pathogens. 2015;**11**(8):e1005129

[107] Wongsuk T, Pumeesat P, Luplertlop N. Fungal quorum sensing molecules: Role in fungal morphogenesis and pathogenicity. Journal of Basic Microbiology. 2016;**56**(5):440-447

[108] Williams P. Quorum sensing, communication and cross-kingdom signalling in the bac-

[109] Hazen KC, Cutler JE. Autoregulation of germ tube formation by *Candida albicans*.

[110] Hornby JM, Jensen EC, Lisec AD, Tasto JJ, Jahnke B, Shoemaker R, et al. Quorum sensing in the dimorphic fungus *Candida albicans* is mediated by farnesol. Applied and

[111] Ramage G, Saville SP, Wickes BL, López-Ribot JL. Inhibition of *Candida albicans* biofilm formation by farnesol, a quorum-sensing molecule. Applied and Environmental

[112] Alem MAS, Oteef MDY, Flowers TH, Douglas LJ. Production of tyrosol by *Candida albicans* biofilms and its role in quorum sensing and biofilm development. Eukaryotic

[113] Chen H, Fujita M, Feng Q, Clardy J, Fink GR. Tyrosol is a quorum-sensing molecule in *Candida albicans*. Proceedings of the National Academy of Sciences. 2004;

[114] Förster TM, Mogavero S, Dräger A, Graf K, Polke M, Jacobsen ID, et al. Enemies and brothers in arms: *Candida albicans* and gram-positive bacteria. Cellular Microbiology.

[115] Cugini C, Calfee MW, Farrow JM, Morales DK, Pesci EC, Hogan DA. Farnesol, a common sesquiterpene, inhibits PQS production in *Pseudomonas aeruginosa*. Molecular

[116] Hogan DA, Vik A, Kolter R. A *Pseudomonas aeruginosa* quorum-sensing molecule influences *Candida albicans* morphology. Molecular Microbiology. 2004;**54**(5):1212-1223

of Microbiology. 2015;**69**:71-92

Nature Reviews. Microbiology. 2010;**8**(5):340-349

rat. Critical Care Medicine. 2009;**37**(3):1062-1067

terial world. Microbiology. 2007;**153**(12):3923-3938

Environmental Microbiology. 2001;**67**(7):2982-2992

Infection and Immunity. 1979;**24**(3):661-666

Microbiology. 2002;**68**(11):5459-5463

Cell. 2006;**5**(10):1770-1779

**101**(14):5048-5052

2016;**18**(12):1709-1715

Microbiology. 2007;**65**(4):896-906

[103] Nobile CJ, Johnson AD. *Candida albicans* biofilms and human disease. Annual Review of Microbiology. 2015;**69**:71-92

[90] Garcia-Perez JE, Mathé L, Humblet-Baron S, Braem A, Lagrou K, Van Dijck P, et al. A framework for understanding the evasion of host immunity by *Candida* biofilms.

[91] Williams DW, Jordan RPC, Wei X-Q, Alves CT, Wise MP, Wilson MJ, et al. Interactions of *Candida albicans* with host epithelial surfaces. Journal of Oral Microbiology. 2013;**5**

[92] Höfs S, Mogavero S, Hube B. Interaction of *Candida albicans* with host cells: Virulence factors, host defense, escape strategies, and the microbiota. Journal of Microbiology.

[93] Netea MG, Joosten LA, van der Meer JW, Kullberg BJ, van de Veerdonk FL. Immune defence against *Candida* fungal infections. Nature Reviews. Immunology. 2015;**15**(10):

[94] Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich J-M, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-

[95] Mitchell KF, Zarnowski R, Sanchez H, Edward JA, Reinicke EL, Nett JE, et al. Community participation in biofilm matrix assembly and function. Proceedings of the National Academy of Sciences of the United States of America. 2015;**112**(13):4092-4097

[96] Mathews J, Patel M. Bacterial endotoxins and microorganisms in the oral cavities of patients on cancer therapy. Davis D, editor. Microbial Pathogenesis. 2018;**123**(1):190-195

[97] Katragkou A, Simitsopoulou M, Chatzimoschou A, Georgiadou E, Walsh TJ, Roilides E. Effects of interferon-γ and granulocyte colony-stimulating factor on antifungal activity of human polymorphonuclear neutrophils against *Candida albicans* grown as bio-

[98] Xie Z, Thompson A, Sobue T, Kashleva H, Xu H, Vasilakos J, et al. *Candida albicans* biofilms do not trigger reactive oxygen species and evade neutrophil killing. The Journal

[99] Zawrotniak M, Bochenska O, Karkowska-Kuleta J, Seweryn-Ozog K, Aoki W, Ueda M, et al. Aspartic proteases and major cell wall components in *Candida albicans* trigger the release of neutrophil extracellular traps. Frontiers in Cellular and Infection

[100] Chandra J, McCormick TS, Imamura Y, Mukherjee PK, Ghannoum MA. Interaction of *Candida albicans* with adherent human peripheral blood mononuclear cells increases *C*. *albicans* biofilm formation and results in differential expression of pro- and anti-

[101] Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune

[102] Kean R, McKloud E, Townsend EM, Sherry L, Delaney C, Jones BL, et al. The comparative efficacy of antiseptics against *Candida auris* biofilms. International Journal of

inflammatory cytokines. Infection and Immunity. 2007;**75**(5):2612-2620

Antimicrobial Agents. 2018;**S0924-8579**(18):30138-9. In Press

mediated inflammation. Immunity. 2011;**34**(4):566-578

films or planktonic cells. Cytokine. 2011;**55**(3):330-334

of Infectious Diseases. 2012;**206**(12):1936-1945

Microbiology. 2017;**7**(September):1-21

system. PLoS Pathogens. 2006;**2**(4):e35

Frontiers in Immunology. 2018;**9**:538

2016;**54**(3):149-169

630-642

138 Candida Albicans

[117] Fernandes RA, Monteiro DR, Arias LS, Fernandes GL, Delbem ACB, Barbosa DB. Biofilm formation by *Candida albicans* and *Streptococcus mutans* in the presence of farnesol: A quantitative evaluation. Biofouling. 2016;**32**(3):329-338

[130] Burmølle M, Webb JS, Rao D, Hansen LH, Sørensen SJ, Kjelleberg S. Enhanced biofilm formation and increased resistance to antimicrobial agents and bacterial invasion are caused by synergistic interactions in multispecies biofilms. Applied and Environmental

Interactions of *Candida albicans* Cells with Aerobic and Anaerobic Bacteria during Formation…

http://dx.doi.org/10.5772/intechopen.81537

[131] Roberts AP, Kreth J. The impact of horizontal gene transfer on the adaptive ability of the human oral microbiome. Frontiers in Cellular and Infection Microbiology.

[132] Gulati M, Nobile CJ. *Candida albicans* biofilms: development, regulation, and molecular

[133] Stewart PS. Mechanisms of antibiotic resistance in bacterial biofilms. International

[134] Vediyappan G, Rossignol T, D'Enfert C. Interaction of *Candida albicans* biofilms with antifungals: Transcriptional response and binding of antifungals to beta-glucans.

[135] Mulcahy H, Charron-Mazenod L, Lewenza S. Extracellular DNA chelates cations and induces antibiotic resistance in *Pseudomonas aeruginosa* biofilms. PLoS Pathogens.

[136] Connell SR, Tracz DM, Nierhaus KH, Taylor DE. Ribosomal protection proteins and their mechanism of tetracycline resistance. Antimicrobial Agents and Chemotherapy.

[137] Domingues S, Nielsen KM. Membrane vesicles and horizontal gene transfer in prokary-

[138] Ciofu O, Beveridge TJ, Kadurugamuwa J, Walther-Rasmussen J, Høiby N. Chromosomal beta-lactamase is packaged into membrane vesicles and secreted from *Pseudomonas*

[139] Singh S, Singh SK, Chowdhury I, Singh R. Understanding the mechanism of bacterial biofilms resistance to antimicrobial agents. The Open Microbiology Journal. 2017;

[140] Martins M, Henriques M, Lopez-Ribot JL, Oliveira R. Addition of DNase improves the in vitro activity of antifungal drugs against *Candida albicans* biofilms. Mycoses.

[141] Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. International Journal of Antimicrobial Agents. 2010;**35**(4):322-332

[142] Wang Z, De La Fuente-Núñez C, Shen Y, Haapasalo M, Hancock REW. Treatment of oral multispecies biofilms by an anti-biofilm peptide. PLoS One. 2015;**10**(7):1-16 [143] Zhang T, Wang Z, Hancock REW, De La Fuente-Núñez C, Haapasalo M. Treatment of

oral biofilms by a D-enantiomeric peptide. PLoS One. 2016;**11**(11):1-16

*aeruginosa*. The Journal of Antimicrobial Chemotherapy. 2000;**45**(1):9-13

mechanisms. Microbes and Infection. 2016;**18**(5):310-321

Journal of Medical Microbiology. 2002;**292**(2):107-113

otes. Current Opinion in Microbiology. 2017;**38**:16-21

Antimicrobial Agents and Chemotherapy. 2010;**54**(5):2096-2111

Microbiology. 2006;**72**(6):3916-3923

2014;**4**(September):1-9

2008;**4**(11):e1000213

2003;**47**(12):3675-3681

**11**(1):53-62

2012;**55**(1):80-85

[130] Burmølle M, Webb JS, Rao D, Hansen LH, Sørensen SJ, Kjelleberg S. Enhanced biofilm formation and increased resistance to antimicrobial agents and bacterial invasion are caused by synergistic interactions in multispecies biofilms. Applied and Environmental Microbiology. 2006;**72**(6):3916-3923

[117] Fernandes RA, Monteiro DR, Arias LS, Fernandes GL, Delbem ACB, Barbosa DB. Biofilm formation by *Candida albicans* and *Streptococcus mutans* in the presence of farnesol: A

[118] Koo H. Inhibition of *Streptococcus* mutans biofilm accumulation and polysaccharide production by apigenin and tt-farnesol. The Journal of Antimicrobial Chemotherapy.

[119] Kim D, Sengupta A, Niepa THR, Lee B-H, Weljie A, Freitas-Blanco VS, et al. *Candida albicans* stimulates *Streptococcus mutans* microcolony development via cross-kingdom

[120] Jarosz LM, Deng DM, van der Mei HC, Crielaard W, Krom BP. *Streptococcus mutans* competence-stimulating peptide inhibits *Candida albicans* hypha formation. Eukaryotic

[121] Sztajer H, Szafranski SP, Tomasch J, Reck M, Nimtz M, Rohde M, et al. Cross-feeding and interkingdom communication in dual-species biofilms of *Streptococcus mutans* and

[122] Jack AA, Daniels DE, Jepson MA, Vickerman MM, Lamont RJ, Jenkinson HF, et al. *Streptococcus gordonii* comCDE (competence) operon modulates biofilm formation with

[123] Bachtiar EW, Bachtiar BM, Jarosz LM, Amir LR, Sunarto H, Ganin H, et al. AI-2 of *Aggregatibacter actinomycetemcomitans* inhibits *Candida albicans* biofilm formation.

[124] Akiyama H, Oono T, Huh W-K, Yamasaki O, Ogawa S, Katsuyama M, et al. Actions of farnesol and xylitol against *Staphylococcus aureus*. Chemotherapy. 2002;**48**(3):122-128

[125] Unnanuntana A, Bonsignore L, Shirtliff ME, Greenfield EM. The effects of farnesol on *Staphylococcus aureus* biofilms and osteoblasts. An in vitro study. The Journal of Bone

[126] Kong EF, Tsui C, Kucharíková S, Van Dijck P, Jabra-Rizk MA. Modulation of *Staphylococcus aureus* response to antimicrobials by the *Candida albicans* quorum sensing molecule farne-

[127] Décanis N, Savignac K, Rouabhia M. Farnesol promotes epithelial cell defense against *Candida albicans* through Toll-like receptor 2 expression, interleukin-6 and human

[128] Leonhardt I, Spielberg S, Weber M, Albrecht-Eckardt D, Bläss M, Claus R, et al. The fungal quorum-sensing molecule farnesol activates innate immune cells but suppresses

[129] Gilbert P, Das J, Foley I. Biofilm susceptibility to antimicrobials. Advances in Dental

quantitative evaluation. Biofouling. 2016;**32**(3):329-338

biofilm-derived metabolites. Scientific Reports. 2017;**7**(1):41332

*Candida albicans*. The ISME Journal. 2014;**8**(11):2256-2271

*Candida albicans*. Microbiology. 2015;**161**(Pt 2):411-421

Frontiers in Cellular and Infection Microbiology. 2014;**4**:94

and Joint Surgery. American Volume. 2009;**91**(11):2683-2692

β-defensin 2 production. Cytokine. 2009;**45**(2):132-140

cellular adaptive immunity. MBio. 2015;**6**(2):e00143-15

Research. 1997;**11**(1):160-167

sol. Antimicrobial Agents and Chemotherapy. 2017;**61**(12):e01573-17

2003;**52**(5):782-789

140 Candida Albicans

Cell. 2009;**8**(11):1658-1664

[144] De La Fuente-Núñez C, Reffuveille F, Mansour SC, Reckseidler-Zenteno SL, Hernández D, Brackman G, et al. D-Enantiomeric Peptides that eradicate wild-type and multidrug-resistant biofilms and protect against lethal *Pseudomonas aeruginosa* infections. Chemistry & Biology. 2015;**22**(2):196-205

**Section 4**

**New Therapeutic and Management**

**New Therapeutic and Management**

[144] De La Fuente-Núñez C, Reffuveille F, Mansour SC, Reckseidler-Zenteno SL, Hernández D, Brackman G, et al. D-Enantiomeric Peptides that eradicate wild-type and multidrug-resistant biofilms and protect against lethal *Pseudomonas aeruginosa* infections.

[145] Shankar Raut J, Mohan Karuppayil S. Phytochemicals as inhibitors of *Candida* biofilm.

[146] Basavaraju M, Sisnity VS, Palaparthy R, Addanki PK. Quorum quenching: Signal jamming in dental plaque biofilms. Journal of Dental Sciences. 2016;**11**(4):349-352

[147] Lazar V. Quorum sensing in biofilms—How to destroy the bacterial citadels or their

[148] Hisajima T, Maruyama N, Tanabe Y, Ishibashi H, Yamada T, Makimura K, et al. Protective effects of farnesol against oral candidiasis in mice. Microbiology and Immu-

[149] Rosseti IB, Chagas LR, Costa MS. Photodynamic antimicrobial chemotherapy (PACT) inhibits biofilm formation by *Candida albicans*, increasing both ROS production and

[150] Costa ACBP, Campos Rasteiro VM, Da Silva Hashimoto ESH, Araújo CF, Pereira CA, Junqueira JC, et al. Effect of erythrosine- and LED-mediated photodynamic therapy on buccal candidiasis infection of immunosuppressed mice and *Candida albicans* adherence to buccal epithelial cells. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology.

membrane permeability. Lasers in Medical Science. 2014;**29**(3):1059-1064

Chemistry & Biology. 2015;**22**(2):196-205

Current Pharmaceutical Design. 2016;**22**(27):4111-4134

cohesion/power? Anaerobe. 2011;**17**(6):280-285

nology. 2008;**52**(7):237-333

142 Candida Albicans

2012;**114**(1):67-74

**Chapter 7**

**Provisional chapter**

**Nanoparticles as New Therapeutic Agents against**

**Nanoparticles as New Therapeutic Agents against**

DOI: 10.5772/intechopen.80379

*Candida albicans* is an opportunistic dimorphic yeast. This organism is pathogen associated to superficial and systemic infections. Actually, *Candida albicans* represents an emergent pathogen especially in a patient with some immunity compromises. Added to this, the use of antifungal in an indiscriminate form has increased the resistance of the existing drugs. In this aspect, the nanotechnology generates the possibility of creating new therapeutic agents. Nanoparticles are structures of 1–100 nm with special physicochemical characteristics that allow it to function as therapeutic agents or as carriers of these. Palladium, silver, and gold metallic nanoparticles and iron, titanium, zinc, and copper oxides have been used as growth inhibitors. These nanoparticles have been proved alone or in form of nanocomposites. The objective of this chapter is to describe the state of the art of the use of nanoparticles as inhibitors of the growth of *Candida albicans*, as well as the

Candidiasis is one of the most common infections worldwide. These diseases are generated by *Candida albicans* and *Candida* non-*albicans* group. *Candida albicans* is an opportunistic dimorphic yeast. It is a commensal organism in gastrointestinal, respiratory, and genitourinary

most relevant results regarding the mechanisms involved in this inhibition.

**Keywords:** nanotechnology, resistance, metallic and oxide nanoparticles

© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,

distribution, and reproduction in any medium, provided the original work is properly cited.

*Candida albicans*

*Candida albicans*

Hilda Amelia Piñón Castillo,

Hilda Amelia Piñón Castillo,

Laila Nayzzel Muñoz Castellanos, Rigoberto Martínez Chamorro, Reyna Reyes Martínez and Erasmo Orrantia Borunda

Laila Nayzzel Muñoz Castellanos, Rigoberto Martínez Chamorro, Reyna Reyes Martínez and Erasmo Orrantia Borunda

http://dx.doi.org/10.5772/intechopen.80379

**Abstract**

**1. Introduction**

Additional information is available at the end of the chapter

Additional information is available at the end of the chapter

#### **Nanoparticles as New Therapeutic Agents against** *Candida albicans* **Nanoparticles as New Therapeutic Agents against**  *Candida albicans*

DOI: 10.5772/intechopen.80379

Hilda Amelia Piñón Castillo, Laila Nayzzel Muñoz Castellanos, Rigoberto Martínez Chamorro, Reyna Reyes Martínez and Erasmo Orrantia Borunda Hilda Amelia Piñón Castillo, Laila Nayzzel Muñoz Castellanos, Rigoberto Martínez Chamorro, Reyna Reyes Martínez and Erasmo Orrantia Borunda

Additional information is available at the end of the chapter Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/intechopen.80379

**Abstract**

*Candida albicans* is an opportunistic dimorphic yeast. This organism is pathogen associated to superficial and systemic infections. Actually, *Candida albicans* represents an emergent pathogen especially in a patient with some immunity compromises. Added to this, the use of antifungal in an indiscriminate form has increased the resistance of the existing drugs. In this aspect, the nanotechnology generates the possibility of creating new therapeutic agents. Nanoparticles are structures of 1–100 nm with special physicochemical characteristics that allow it to function as therapeutic agents or as carriers of these. Palladium, silver, and gold metallic nanoparticles and iron, titanium, zinc, and copper oxides have been used as growth inhibitors. These nanoparticles have been proved alone or in form of nanocomposites. The objective of this chapter is to describe the state of the art of the use of nanoparticles as inhibitors of the growth of *Candida albicans*, as well as the most relevant results regarding the mechanisms involved in this inhibition.

**Keywords:** nanotechnology, resistance, metallic and oxide nanoparticles

#### **1. Introduction**

Candidiasis is one of the most common infections worldwide. These diseases are generated by *Candida albicans* and *Candida* non-*albicans* group. *Candida albicans* is an opportunistic dimorphic yeast. It is a commensal organism in gastrointestinal, respiratory, and genitourinary

© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

tracts. Normally, it is a harmless organism that can turn into an opportunistic organism in immunocompromised or immunologically deficient individuals [1–3].

pharmaceutical agent that can be specific. As pharmaceutical agent nanoparticles such as copper, silver, and palladium, among others, have been employed in order to inhibit the growth

Nanoparticles as New Therapeutic Agents against *Candida albicans*

http://dx.doi.org/10.5772/intechopen.80379

The objective of this chapter is to describe the state of the art of the use of nanoparticles as inhibitors of the growth of *Candida albicans*, as well as the most relevant results regarding the

Fungi form one of the largest eukaryotic kingdoms; they have a very broad function of decomposing biopolymers and different compounds in dead or alive hosts, as well as synthesizing bioactive compounds. The yeast *Candida albicans* originally was described as Blastomycetes class belonging to Monilial order and Cryptococcaceae family. Actually, with gene sequencing, the new taxonomy classifies *Candida albicans* into *Ascomycota*, (dikaryon-producing fungi),

*Candida albicans* is a common commensal on mucosal surfaces under normal conditions, mainly of the gastrointestinal and vaginal tracts. The commensal stage is frequently described as harmless to the host, and the fungus is controlled by the normal microbiota, epithelial barriers, and the innate immune system [14, 15]. This is the most important opportunistic medical pathogenic fungus, causing candidiasis, which is an acute, subacute, or chronic infection involving any part of the body [15]. The weakening of the defense mechanisms of the host and the adaptation capacity of the microorganism turn this fungus into an aggressive pathogen, starting with superficial infections into a systemic process, mainly in immunosuppressed or

*Candida albicans* cell wall is composed mainly of carbohydrates; three basic main constituents

**2.** Unbranched polymers of N-acetyl-D-glucosamine (GlcNAc) with β-1,4 bonds; the chitin, which contributes to the fiber insolubility; and theβ-1,3 glucan-chitin complex, which is the major constituent of the inner wall. β-1,6 glucan links the components of the inner and outer walls; thus, chitin and β-1,3 are structural polysaccharides and convey strength and

**3.** Finally mannose polymers, mannans, covalently associated with proteins (glucomannan

**1.** Branched polymers of glucose with β-1,3 and β-1,6 bonds, they are called β-glucans.

of any microorganism, in particular, *Candida albicans*.

*Hemiascomycetes* subclass, and *Saccharomycotina* order [12, 13].

mechanisms involved in this inhibition.

**2.** *Candida albicans* **taxonomy**

HIV patients [16].

are polysaccharides:

proteins).

**3.** *Candida albicans* **cell wall**

shape to the cell wall [15, 17, 18].

*Candida albicans* represents the predominant yeast in oral, genital, and cutaneous infections (≥90%) [2, 4, 5]. However, the invasion of blood torrent by *Candida* species is the infection more frequently diagnosed. The frequency of *Candida albicans* isolated in candidemia is of 46.3%, followed by *C. glabrata* (24.4%) [3, 6]. The mortality frequency in patients with invasive candidemia ranges from 40 to >70%, generating a loss of about 1.7 billion dollars every year [1, 7].

For the treatment of invasive infection by *Candida*, few options are available. The polyenes (amphotericin B and nystatin) are the chosen treatment by excellence. However other antifungals are used as azoles [8]. The azoles (fluconazole and itraconazole) and new azoles (ravuconazole, posaconazole, and voriconazole) are selected for prophylaxis, empirical therapy, and diagnostic-driven therapy [9]. The use of echinocandins (caspofungin, anidulafungin, and micafungin) is driven to therapy on invasive candidiasis [1].

However, the adverse effects of antifungal therapy as nephrotoxicity, red blood cell (RBC) toxicity, and arrhythmias for amphotericin B, hepatotoxicity associated with fluconazole, cardiotoxicity and gastrointestinal (GIT) disturbances attributed to itraconazole, voriconazole exhibiting neurological and hepatic toxicities, and posaconazole shown to elevate serum aminotransferase levels and cause mild-to-moderate hepatic toxicity limit its use.  Azoles and polyenes have ergosterol as a target from the cell membrane, and the ergosterol has a high similarity between ergosterol and human cholesterol [8]. Azoles inhibit the ergosterol biosynthesis, specifically the lanosterol 14α-demethylase. This generates sterol precursor accumulation, resulting in a cell membrane instability and the loss of viability [3].

The echinocandins are more specific for fungi. This therapeutic antifungal inhibits the enzyme 1,3-b-D-glucan synthase and generates the depletion of polymer synthesis and osmotic stability loss [1, 10].

Due to the discriminated antifungal agent use, *Candida albicans* has developed different resistance mechanisms. Three principal mechanisms have been reported: the efflux pump, which is a membrane transport protein that ejects the azoles out of the cell; the structural changes of the enzyme target, mutations on lanosterol 14 α-demethylase, changing the three-dimensional structure, and, as consequence, the decreased affinity for this enzyme; and the last mechanism is the increase in the production of the target enzyme; this generates the inhibition of only a portion of the enzyme, and the rest are still active [1–3, 8, 11].

On the other hand, the survival characteristics of *Candida albicans* in the host make this organism difficult to kill. The virulence factors include the biofilm formation capacity, the yeasthyphae morphogenesis, the adhesion to surfaces, and the capacity to secrete enzymes as hydrolases.

Because of this, the research for more specific antifungal therapies has been the focus of attention. In this area, the nanotechnology offers an opportunity to design and create a new pharmaceutical agent that can be specific. As pharmaceutical agent nanoparticles such as copper, silver, and palladium, among others, have been employed in order to inhibit the growth of any microorganism, in particular, *Candida albicans*.

The objective of this chapter is to describe the state of the art of the use of nanoparticles as inhibitors of the growth of *Candida albicans*, as well as the most relevant results regarding the mechanisms involved in this inhibition.

### **2.** *Candida albicans* **taxonomy**

tracts. Normally, it is a harmless organism that can turn into an opportunistic organism in

*Candida albicans* represents the predominant yeast in oral, genital, and cutaneous infections (≥90%) [2, 4, 5]. However, the invasion of blood torrent by *Candida* species is the infection more frequently diagnosed. The frequency of *Candida albicans* isolated in candidemia is of 46.3%, followed by *C. glabrata* (24.4%) [3, 6]. The mortality frequency in patients with invasive candidemia ranges from 40 to >70%, generating a loss of about 1.7 billion dollars every year [1, 7]. For the treatment of invasive infection by *Candida*, few options are available. The polyenes (amphotericin B and nystatin) are the chosen treatment by excellence. However other antifungals are used as azoles [8]. The azoles (fluconazole and itraconazole) and new azoles (ravuconazole, posaconazole, and voriconazole) are selected for prophylaxis, empirical therapy, and diagnostic-driven therapy [9]. The use of echinocandins (caspofungin, anidulafungin, and

However, the adverse effects of antifungal therapy as nephrotoxicity, red blood cell (RBC) toxicity, and arrhythmias for amphotericin B, hepatotoxicity associated with fluconazole, cardiotoxicity and gastrointestinal (GIT) disturbances attributed to itraconazole, voriconazole exhibiting neurological and hepatic toxicities, and posaconazole shown to elevate serum aminotransferase levels and cause mild-to-moderate hepatic toxicity limit its use.  Azoles and polyenes have ergosterol as a target from the cell membrane, and the ergosterol has a high similarity between ergosterol and human cholesterol [8]. Azoles inhibit the ergosterol biosynthesis, specifically the lanosterol 14α-demethylase. This generates sterol precursor accumulation, resulting in a cell membrane

The echinocandins are more specific for fungi. This therapeutic antifungal inhibits the enzyme 1,3-b-D-glucan synthase and generates the depletion of polymer synthesis and osmotic stabil-

Due to the discriminated antifungal agent use, *Candida albicans* has developed different resistance mechanisms. Three principal mechanisms have been reported: the efflux pump, which is a membrane transport protein that ejects the azoles out of the cell; the structural changes of the enzyme target, mutations on lanosterol 14 α-demethylase, changing the three-dimensional structure, and, as consequence, the decreased affinity for this enzyme; and the last mechanism is the increase in the production of the target enzyme; this generates the inhibition of only a

On the other hand, the survival characteristics of *Candida albicans* in the host make this organism difficult to kill. The virulence factors include the biofilm formation capacity, the yeasthyphae morphogenesis, the adhesion to surfaces, and the capacity to secrete enzymes as

Because of this, the research for more specific antifungal therapies has been the focus of attention. In this area, the nanotechnology offers an opportunity to design and create a new

immunocompromised or immunologically deficient individuals [1–3].

micafungin) is driven to therapy on invasive candidiasis [1].

portion of the enzyme, and the rest are still active [1–3, 8, 11].

instability and the loss of viability [3].

ity loss [1, 10].

146 Candida Albicans

hydrolases.

Fungi form one of the largest eukaryotic kingdoms; they have a very broad function of decomposing biopolymers and different compounds in dead or alive hosts, as well as synthesizing bioactive compounds. The yeast *Candida albicans* originally was described as Blastomycetes class belonging to Monilial order and Cryptococcaceae family. Actually, with gene sequencing, the new taxonomy classifies *Candida albicans* into *Ascomycota*, (dikaryon-producing fungi), *Hemiascomycetes* subclass, and *Saccharomycotina* order [12, 13].

*Candida albicans* is a common commensal on mucosal surfaces under normal conditions, mainly of the gastrointestinal and vaginal tracts. The commensal stage is frequently described as harmless to the host, and the fungus is controlled by the normal microbiota, epithelial barriers, and the innate immune system [14, 15]. This is the most important opportunistic medical pathogenic fungus, causing candidiasis, which is an acute, subacute, or chronic infection involving any part of the body [15]. The weakening of the defense mechanisms of the host and the adaptation capacity of the microorganism turn this fungus into an aggressive pathogen, starting with superficial infections into a systemic process, mainly in immunosuppressed or HIV patients [16].

#### **3.** *Candida albicans* **cell wall**

*Candida albicans* cell wall is composed mainly of carbohydrates; three basic main constituents are polysaccharides:

The mannan of the outer cell wall is less structured but allows this fungus breakage of epithelial barriers or dysfunction of the immune system converting *Candida albicans* from a commensal to a pathogen. The cell walls also contain proteins, 6–25%, and minor amounts of lipids, 1–7% [15, 17, 18].

pseudohyphae, yeast cells, and an extracellular matrix, where the hyphae play an integral role within this complex [26]. Biofilm formation presents an initial adherence of yeast cells (0–2 h), followed by germination and microcolony formation (2–4 h), filamentation (4–6 h), monolayer development (6–8 h), proliferation (8–24 h), and maturation (24–48 h). Serum and saliva preconditioning films and *Candida albicans* preconditioning films increased the initial attachment of the fungus but had minimal effect on subsequent biofilm formation [25, 28]. This kind of biofilm has clinical repercussions because it is the target of both chemical and immunological antifungals. Due of their intrinsic resistance to almost all antifungals in clinical use, increased resistance to this therapy, and the ability of cells within biofilms to withstand host immune defenses, the antifungal resistance of biofilms results most probably from the conjunction of

Nanoparticles as New Therapeutic Agents against *Candida albicans*

http://dx.doi.org/10.5772/intechopen.80379

In order for *Candida albicans* to survive, these microorganisms have developed diverse mechanisms. Biofilm formation, enzyme modification, and the pump efflux are the mechanisms reported to antibiotic resistance [29]. As described previously, biofilms are a complex of cells, DNA, and polymeric matrix, among others. The polymeric matrix has a crucial role in the antifungal resistance since it does not allow antibiotic penetration inside the biofilm. This

Resistance to azole antifungal has been described in three forms: [1] change in the affinity of cytochrome P450 sterol 14α-demethylase (gen Erg11p), [2] increase in the enzyme expression, and [3] changes in the sterol desaturase. Other alterations in an enzyme involved in the cell

The pump efflux ejects the azoles outside the cell, without any effect inside of it. This efflux is mediated by an ATP-binding cassette (ABC) and the major facilitator superfamily. This is a complex family of genes that involve several CDR genes, including core membrane pore composed by ABC segments in the membrane; two segments are in the cytosolic side, which

It is an important highlight that this resistance could be a derivative in the resistance to other

*Candida albicans* resistance could be due to one or a combination of all the resistance mecha-

Nanotechnology is a new technology which manipulates the matter in a nanoscale order (1 × 10−9 m). In this order, the nanoparticles have been used as antimicrobial, as antifungal, or as carried molecules. Nanoparticles have a size from 1–100 nm on any of this dimension. In

several mechanisms that act in a time-dependent manner [26].

**6.** *Candida albicans* **resistance mechanisms**

phenomenon helps the internal cell to survive [25].

wall construction have been described [29, 30].

**7. Nanotechnology as an antifungal**

antifungals.

nisms described.

provide energy to pump the antibiotic outside of the cell [25, 29, 30].

This arrangement is responsible for its cell morphology and provides protection to the cell against physical, chemical, and biological (immune host system) aggression [16].

Likewise, the cell wall participates in both growth and morphological transitions between yeast and hyphae; this conversion from the unicellular yeast to multicellular filamentous fungus is essential for *Candida* virulence [19]. It has cell surface proteins linked to glycosylphosphatidylinositol (GPI) [20], including an N-terminal signal sequence and a C-terminal GPI-anchor addition signal; some of these proteins are secreted to the extracellular environment, but do not remain cell associated. Some of them are hydrolytic enzymes, which hydrolyze complex substrates into small units, to carry out into the cell as a source of nutrition. If these polymers are host targets, all of these facilitate colonization or invasion of *Candida albicans*, and then such enzymes also function as virulence factors [17]. For therapeutic strategies, to establish the functional relationships between *Candida albicans* cell wall's proteins and virulence is a challenge [20].

#### **4.** *Candida albicans* **virulence factors**

*Candida* spp. invade several anatomical hosts, mainly in patients who are immunocompromised or debilitated. This organism expresses several virulence factors that allow the hostpathogen interaction and that lead to the establishment of infection [21, 22].

Virulence factors include host recognition biomolecules (adhesins) due to cell surface hydrophobicity which enhanced adherence and resistance to phagocytosis; another important factor is its ability to grow either in yeast or in hyphal form (dimorphism, especially in the presence of N-acetyl-D-glucosamine) [23], secreting aspartyl proteases and phospholipases [21].

The phenomenon of the quorum sensing (QS) has been described as a contributor to morphogenesis, playing a role in regulating the yeast to filamentous fungus; one of the conditions is the dependence on cell density associated with the regulation by QS. The QS has an important role in the ability of *Candida albicans* to be virulent and survive within the host [23]. *Candida albicans* uses multiple redundant and/or synergistic signaling pathways to integrate host signals to promote hyphal development, tissue invasion, and virulence during infection, exacerbating the pathogenesis of invasive candidiasis [24].

#### **5.** *Candida albicans* **biofilm formation**

*Candida* virulence is a result of its capacity to form biofilms on the surface of biomaterials and on catheters and prosthetic devices [25–27]. *Candida albicans* biofilms are composed of hyphae, pseudohyphae, yeast cells, and an extracellular matrix, where the hyphae play an integral role within this complex [26]. Biofilm formation presents an initial adherence of yeast cells (0–2 h), followed by germination and microcolony formation (2–4 h), filamentation (4–6 h), monolayer development (6–8 h), proliferation (8–24 h), and maturation (24–48 h). Serum and saliva preconditioning films and *Candida albicans* preconditioning films increased the initial attachment of the fungus but had minimal effect on subsequent biofilm formation [25, 28]. This kind of biofilm has clinical repercussions because it is the target of both chemical and immunological antifungals. Due of their intrinsic resistance to almost all antifungals in clinical use, increased resistance to this therapy, and the ability of cells within biofilms to withstand host immune defenses, the antifungal resistance of biofilms results most probably from the conjunction of several mechanisms that act in a time-dependent manner [26].

#### **6.** *Candida albicans* **resistance mechanisms**

The mannan of the outer cell wall is less structured but allows this fungus breakage of epithelial barriers or dysfunction of the immune system converting *Candida albicans* from a commensal to a pathogen. The cell walls also contain proteins, 6–25%, and minor amounts of

This arrangement is responsible for its cell morphology and provides protection to the cell

Likewise, the cell wall participates in both growth and morphological transitions between yeast and hyphae; this conversion from the unicellular yeast to multicellular filamentous fungus is essential for *Candida* virulence [19]. It has cell surface proteins linked to glycosylphosphatidylinositol (GPI) [20], including an N-terminal signal sequence and a C-terminal GPI-anchor addition signal; some of these proteins are secreted to the extracellular environment, but do not remain cell associated. Some of them are hydrolytic enzymes, which hydrolyze complex substrates into small units, to carry out into the cell as a source of nutrition. If these polymers are host targets, all of these facilitate colonization or invasion of *Candida albicans*, and then such enzymes also function as virulence factors [17]. For therapeutic strategies, to establish the functional relationships between *Candida albicans* cell wall's proteins and

*Candida* spp. invade several anatomical hosts, mainly in patients who are immunocompromised or debilitated. This organism expresses several virulence factors that allow the host-

Virulence factors include host recognition biomolecules (adhesins) due to cell surface hydrophobicity which enhanced adherence and resistance to phagocytosis; another important factor is its ability to grow either in yeast or in hyphal form (dimorphism, especially in the presence of N-acetyl-D-glucosamine) [23], secreting aspartyl proteases and phospholipases [21].

The phenomenon of the quorum sensing (QS) has been described as a contributor to morphogenesis, playing a role in regulating the yeast to filamentous fungus; one of the conditions is the dependence on cell density associated with the regulation by QS. The QS has an important role in the ability of *Candida albicans* to be virulent and survive within the host [23]. *Candida albicans* uses multiple redundant and/or synergistic signaling pathways to integrate host signals to promote hyphal development, tissue invasion, and virulence during infection,

*Candida* virulence is a result of its capacity to form biofilms on the surface of biomaterials and on catheters and prosthetic devices [25–27]. *Candida albicans* biofilms are composed of hyphae,

pathogen interaction and that lead to the establishment of infection [21, 22].

exacerbating the pathogenesis of invasive candidiasis [24].

**5.** *Candida albicans* **biofilm formation**

against physical, chemical, and biological (immune host system) aggression [16].

lipids, 1–7% [15, 17, 18].

148 Candida Albicans

virulence is a challenge [20].

**4.** *Candida albicans* **virulence factors**

In order for *Candida albicans* to survive, these microorganisms have developed diverse mechanisms. Biofilm formation, enzyme modification, and the pump efflux are the mechanisms reported to antibiotic resistance [29]. As described previously, biofilms are a complex of cells, DNA, and polymeric matrix, among others. The polymeric matrix has a crucial role in the antifungal resistance since it does not allow antibiotic penetration inside the biofilm. This phenomenon helps the internal cell to survive [25].

Resistance to azole antifungal has been described in three forms: [1] change in the affinity of cytochrome P450 sterol 14α-demethylase (gen Erg11p), [2] increase in the enzyme expression, and [3] changes in the sterol desaturase. Other alterations in an enzyme involved in the cell wall construction have been described [29, 30].

The pump efflux ejects the azoles outside the cell, without any effect inside of it. This efflux is mediated by an ATP-binding cassette (ABC) and the major facilitator superfamily. This is a complex family of genes that involve several CDR genes, including core membrane pore composed by ABC segments in the membrane; two segments are in the cytosolic side, which provide energy to pump the antibiotic outside of the cell [25, 29, 30].

It is an important highlight that this resistance could be a derivative in the resistance to other antifungals.

*Candida albicans* resistance could be due to one or a combination of all the resistance mechanisms described.

#### **7. Nanotechnology as an antifungal**

Nanotechnology is a new technology which manipulates the matter in a nanoscale order (1 × 10−9 m). In this order, the nanoparticles have been used as antimicrobial, as antifungal, or as carried molecules. Nanoparticles have a size from 1–100 nm on any of this dimension. In this scale, nanoparticles have particularity physicochemical characteristics [31]. Within these characteristics, their electron configuration confers an extraordinary quantum effect. These quantum effects enhance their pharmacokinetic effect and generate nanoparticles that can be used as a protein, antibodies, or inclusive specific molecule carriers [32].

**Inhibition test NPs size**

16.7 ± 0.25 mm (inhibition

12 mm (inhibition zone with 30 μL of solution)

250 μg/mL (MIC) and 500 μg/mL (MFC)

(MFC)

60 μg/mL (MIC90) and 120

20 mm (inhibition zone with 80 μg/20 mL)

21–12 cm in combination with antifungal (inhibition

10.78 μg/mL (MIC) 7.6 ± 0.5 *L. grandis*

zone)

75 ppm reduce 83%/150 ppm (MFC)

zone)

**(nm)**

64 μg/mL (MIC) 12.7 *Pilimelia columellifera* subsp.

10 μg/mL (BIC) 40–55 *Dodonaea viscosa* and *Hyptis*

40–60 μg/mL(MIC) 4–39 Citrus lemon aqueous Juice +

CTAB

10.8 ± 0.8 (inhibition zone) 12–85 Clove extract Detection of

**Synthesis method Capped Reference**

Nanoparticles as New Therapeutic Agents against *Candida albicans*

Detection of functional groups as phenol, alcohol, proteins, heterocyclic amines

functional groups as alcohol, carbonyl, amino groups

compounds

Surrounded by a layer

functional groups such as methoxy, alcohol, carboxilic acid, aliphatic group

2–8 *Monascus purpureus* NR El-Baz et al.,

3.77–33.22 *Pleurotus sajor-caju* NR Musa et al. 2018

2–7 Tulsi leaf extract NR Khatoon et al.,

21.65–41.05 *Phoenix dactylifera* Proteins Oves et al. 2018

10–90 Flower broth of *Tagetes erecta* NR Padalia et al.

2017 [42]

2016 [7]

[38]

[40]

[34]

[46]

[47]

2015 [45]

Ocsoy et al. 2017

Rahisuddin et al. 2015 [48]

Parlinska-Wojtan et al. 2017 [49]

2015 [50]

2017 [51]

Kumar et al. 2013 [44]

Muthamil et al. 2018 [43]

Proteins Wypij et al. 2017 [37]

http://dx.doi.org/10.5772/intechopen.80379

18 mm (inhibition zone) 15–20 *Cassia roxburghii + Ketoconazole* NR Moteriya et al.

40 μg/mL (MIC) 5–95 *Bacillus safensis* Proteins Lateef et al. 2015

18–46 *Gracilaria corticata* Detection of

70 Red cabbage Anthocyanin

08 μg/mL (MIC) 9–130 *Enterococcus faecalis* NR Ashajyothi 2016

12.14 μg/mL (MIC) 47.0 ± 2.0 *J. curcas* Protein layer Kumar et al.

pallida SL19

*suaveolens*

As an antifungal, nanoparticles show cell wall damage, an oxidative stress increase, and DNA interaction [33]. Nevertheless, the NPs toxicity mechanisms are dependent on the nanoparticle nature, size, and shape and capping nature, among other characteristics.

This chapter reviewed some NPs characteristics such as nanoparticle nature, synthesis, size, and shape and their influence on the toxic mechanisms in *Candida albicans* and their influence on the virulence factors.

#### **7.1. Silver nanoparticles**

Silver has been used for several decades as a disinfectant. Inclusively, silver nitrate was used in burns in order to control infections. However, with the discovery of penicillin, the use of silver was slow. Nowadays, the increase of resistance to antifungal puts attention again on the use of silver as an antibiotic, though the use of silver ions implies complications in their solubility and availability [34].

In this sense, the silver nanoparticles (AgNPs) offer a possibility. AgNPs offer the possibility of using minimal doses and act in microorganisms which present antibiotic resistance or decrease the virulence factors.

The use of different AgNPs synthesis methods caused different effects. The general method is the salt reduction by a reducing agent. However, the addition stabilizing agent has been proved. The stabilizing or capping agent limits the NPs' growth, avoids the agglomeration, and controls the shape, size, and superficial charge [35].

The NP synthesis by plant extract or secondary metabolites from microorganisms offers a new possibility. The phenolic compounds, proteins, anthocyanin, and carboxylic acid, among others, work as reducing agent and stabilizing or capping agent [35, 36].

The green AgNPs synthesis through the use of microorganisms as the use of Actinobacteria *Pilimelia columellifera* subsp. pallida [37], *Bacillus* species [38, 39], filamentous fungi *Monascus purpureus* [7], and Macromycetes as *Pleurotus sajor-caju* [40], as well as extract plant as *Tulsi* leaf extract [41] or extract from *Phoenix dactylifera* [34] has been proven. All these methods present inhibition of *Candida albicans*, with different efficiencies (**Table 1**).

The microorganisms *Bacillus amyloliquefaciens* 1853 and *Bacillus subtilis* 10,833 have been used for the AgNPs synthesis. Culture media were employed as a reducing agent. The scanning electronic microscopy has shown AgNPs produced with capping. *Bacillus* strains have been used in the AgNPS production. *Bacillus amyloliquefaciens* strain 1853 produced AgNPs with a size of 1.071 and other of 73.83 nm. The *Bacillus* subtilis strain 10,833 produced tree population sizes of AgNPs at 1.863, 10.866, and 135.78 nm. AgNPs produced by both microorganisms were employed to evaluate the *Candida albicans* inhibition. No differences were found between AgNPs; inclusive addition of antibiotic with the AgNPs does not improve the inhibition [38].

this scale, nanoparticles have particularity physicochemical characteristics [31]. Within these characteristics, their electron configuration confers an extraordinary quantum effect. These quantum effects enhance their pharmacokinetic effect and generate nanoparticles that can be

As an antifungal, nanoparticles show cell wall damage, an oxidative stress increase, and DNA interaction [33]. Nevertheless, the NPs toxicity mechanisms are dependent on the nanopar-

This chapter reviewed some NPs characteristics such as nanoparticle nature, synthesis, size, and shape and their influence on the toxic mechanisms in *Candida albicans* and their influence

Silver has been used for several decades as a disinfectant. Inclusively, silver nitrate was used in burns in order to control infections. However, with the discovery of penicillin, the use of silver was slow. Nowadays, the increase of resistance to antifungal puts attention again on the use of silver as an antibiotic, though the use of silver ions implies complications in their

In this sense, the silver nanoparticles (AgNPs) offer a possibility. AgNPs offer the possibility of using minimal doses and act in microorganisms which present antibiotic resistance or

The use of different AgNPs synthesis methods caused different effects. The general method is the salt reduction by a reducing agent. However, the addition stabilizing agent has been proved. The stabilizing or capping agent limits the NPs' growth, avoids the agglomeration,

The NP synthesis by plant extract or secondary metabolites from microorganisms offers a new possibility. The phenolic compounds, proteins, anthocyanin, and carboxylic acid, among

The green AgNPs synthesis through the use of microorganisms as the use of Actinobacteria *Pilimelia columellifera* subsp. pallida [37], *Bacillus* species [38, 39], filamentous fungi *Monascus purpureus* [7], and Macromycetes as *Pleurotus sajor-caju* [40], as well as extract plant as *Tulsi* leaf extract [41] or extract from *Phoenix dactylifera* [34] has been proven. All these methods

The microorganisms *Bacillus amyloliquefaciens* 1853 and *Bacillus subtilis* 10,833 have been used for the AgNPs synthesis. Culture media were employed as a reducing agent. The scanning electronic microscopy has shown AgNPs produced with capping. *Bacillus* strains have been used in the AgNPS production. *Bacillus amyloliquefaciens* strain 1853 produced AgNPs with a size of 1.071 and other of 73.83 nm. The *Bacillus* subtilis strain 10,833 produced tree population sizes of AgNPs at 1.863, 10.866, and 135.78 nm. AgNPs produced by both microorganisms were employed to evaluate the *Candida albicans* inhibition. No differences were found between AgNPs; inclusive addition of antibiotic with the AgNPs does not improve the inhibition [38].

used as a protein, antibodies, or inclusive specific molecule carriers [32].

on the virulence factors.

150 Candida Albicans

**7.1. Silver nanoparticles**

solubility and availability [34].

decrease the virulence factors.

and controls the shape, size, and superficial charge [35].

others, work as reducing agent and stabilizing or capping agent [35, 36].

present inhibition of *Candida albicans*, with different efficiencies (**Table 1**).

ticle nature, size, and shape and capping nature, among other characteristics.

The results obtained show the importance of the NPs size, being the smallest nanoparticles which show the highest inhibition [51]. Lara et al. (2015) showed that biofilm exposed to AgNPs exhibits a few *Candida albicans* filamentous formations. Electron microscopy analysis

Nanoparticles as New Therapeutic Agents against *Candida albicans*

http://dx.doi.org/10.5772/intechopen.80379

Besides the AgNPs effect in biofilm, the AgNPs have been used alone showing the inhibition, cell wall damage, and incorporation of Ag into the cell. It was used in combination with different antifungals amphotericin b [51, 56] or nystatin and chlorhexidine digluconate, showing a synergic effect [54]. Other molecules as cationic carboxilane have been used, proving a high *Candida albicans* inhibition with small AgNPs concentration [1.8 mg/mL; [57]]. Also, the AgNPs have been capped with L-3,4-dihydroxyphenyl-alanine, showing a minimal fungicide

The direction in the investigation with silver nanoparticles has been driven in the green synthesis due to the low toxicity generated in the human cell and the increase of the toxicity in bacteria and yeast [59]. Their chemical characteristics as a metallic oxidative state and superficial area, among others, allow the NPs to interact with the microorganism and inhibit their

Due to ZnO low toxicity, ZnO has been used in a medical device such as drug carriers, antibacterial agents, and bioimaging probes, among others. For this reason, the ZnO nanoparticles (ZnONPs) have been used in *Candida albicans* control. The ZnONPs application is reflected by the annual production between 550 and 5500. This is more than 10–100 times higher than any other nanoparticle [60]. As the AgNPs, the ZnONPs characteristics depend on the size, synthesis method, and superficial charge, among others [61]. In order to control these characteristics, the green synthesis method has been used to fabricate ZnONPs with a size, shape,

A promissory ZnONPs application area is their use as antimicrobial. Their effect has been evaluated in soil, plants, bacteria, and fungi [60, 64–66] ZnONPs different synthesis methods

The use of *Atalantia monophylla* extracts produced ZnONPs 30 nm that have effect inhibition in *Candida albicans* growth. The author proposed the ZnONPs interaction with the cell wall, penetration to the cell, ion liberation, and the oxidative stress production, triggering the pro-

The microwave aqueous extract from *Suaeda aegyptiaca* produced ZnONPs with a size of 80 nm with a capping produced by metabolites from the plant. The effect of the capping was studied. ZnONPs produced by precipitation method were studied and compared with the plant extract produced. ZnONPs *Suaeda aegyptiaca* produced a major inhibitory effect than the

Extracts for different plants have been proved to synthesize ZnONPs in order to evaluate the

showed AgNPs accumulation and internalization [55].

and superficial charge with the desirable characteristic [62, 63].

in ZnONPs have a big influence in the *Candida albicans* inhibition [68].

ZnONPs without capping agent, suggesting a synergic effect [68].

toxicity of the resulting nanoparticles in *Candida albicans* inhibition (**Table 2**).

concentration of 31.2–62.5 μg/mL [58].

**7.2. Zinc oxide nanoparticles**

tein, lipid, and DNA oxidation [67].

growth.

**Table 1.** Biogenic synthesized AgNPs against *Candida albicans.*

Clove extract was used in order to produce AgNPs. The high content of eugenol, β-caryophyllene, humulene, chavicol, methyl salicylate, α-ylangene, and eugenone; flavonoids such as eugenin, rhamnetin, kaempferol, and eugenitin; triterpenoids like oleanolic acid, stigmasterol, and campesterol; and several sesquiterpenes allowed the clove to act as a reducing and capping agent in AgNPs synthesis. The DLS analysis showed AgNPs size of 12 and 85 nm. The AgNPs produced to generate a complete inhibition of *Candida albicans* in 40-fold dilution were applied. The results obtained suggest that the functional groups' incorporation into the AgNPs generates a synergism between clove and NPs [49].

In order to evaluate the AgNPs effect on biofilms, some AgNPs have been evaluated. As described, biofilms are a *Candida albicans* virulence factor. The change from yeast to hyphae is crucial for the biofilm process. In this process, *Candida albicans* produces a polysaccharide matrix, carbohydrates, proteins, and signaling molecules [43]. Changes in the structural biofilm conformation of *Candida albicans* exposed to AgNPs were reported [28, 51, 53, 54].

The use of latex plants in the AgNPs green synthesis was proved. *J. curcas* and *L. grandis* extracts produced AgNPs with a size of 47 ± 2.0 nm and 7.6 ± 0.5 nm, respectively. The Fourier transform infrared (FTIR) spectra suggest the incorporation of phenolic OH, amides, amines, and aldehyde in the AgNPs as a stabilizing agent. The smallest AgNPs showed a better effect in plankton and biofilms of *Candida albicans* than the big ones. The AgNPs synthesized proved to be efficient in the inhibition of biofilm formation, changes in morphology and cell lysis when candida albicans was exposed [51].

Also, silver nitrate chemical reduction by sodium citrate was evaluated in intermediate and mature *Candida albicans* biofilms. The preformatted biofilms were exposed to 54 μg/mL of AgNPs. After 5 h of exposition, biofilms showed a decrease in the number of viable cells, and no differences were found in intermediate or mature biofilm [28].

The results obtained show the importance of the NPs size, being the smallest nanoparticles which show the highest inhibition [51]. Lara et al. (2015) showed that biofilm exposed to AgNPs exhibits a few *Candida albicans* filamentous formations. Electron microscopy analysis showed AgNPs accumulation and internalization [55].

Besides the AgNPs effect in biofilm, the AgNPs have been used alone showing the inhibition, cell wall damage, and incorporation of Ag into the cell. It was used in combination with different antifungals amphotericin b [51, 56] or nystatin and chlorhexidine digluconate, showing a synergic effect [54]. Other molecules as cationic carboxilane have been used, proving a high *Candida albicans* inhibition with small AgNPs concentration [1.8 mg/mL; [57]]. Also, the AgNPs have been capped with L-3,4-dihydroxyphenyl-alanine, showing a minimal fungicide concentration of 31.2–62.5 μg/mL [58].

The direction in the investigation with silver nanoparticles has been driven in the green synthesis due to the low toxicity generated in the human cell and the increase of the toxicity in bacteria and yeast [59]. Their chemical characteristics as a metallic oxidative state and superficial area, among others, allow the NPs to interact with the microorganism and inhibit their growth.

#### **7.2. Zinc oxide nanoparticles**

Clove extract was used in order to produce AgNPs. The high content of eugenol, β-caryophyllene, humulene, chavicol, methyl salicylate, α-ylangene, and eugenone; flavonoids such as eugenin, rhamnetin, kaempferol, and eugenitin; triterpenoids like oleanolic acid, stigmasterol, and campesterol; and several sesquiterpenes allowed the clove to act as a reducing and capping agent in AgNPs synthesis. The DLS analysis showed AgNPs size of 12 and 85 nm. The AgNPs produced to generate a complete inhibition of *Candida albicans* in 40-fold dilution were applied. The results obtained suggest that the functional groups' incorporation into the AgNPs generates a

1.012–73.83 *B. amyloliquefaciens* NR

14 mm(inhibition zone) 5–10 *Ocimum sanctum* + CTAB Not visible Aazam and

30 μg/mL (MIC) 4–36 Actinobacterial strain SF23 NR Anasane et al. 2016 [52] <sup>40</sup> <sup>μ</sup>g/mL (MIC) 8–60 Actinobacteria C9 NR

**Synthesis method Capped Reference**

[39]

Zaheer 2016 [35]

1.836–135.78 *B. subtilis* 10,833 NR Ghiut et al. 2018

In order to evaluate the AgNPs effect on biofilms, some AgNPs have been evaluated. As described, biofilms are a *Candida albicans* virulence factor. The change from yeast to hyphae is crucial for the biofilm process. In this process, *Candida albicans* produces a polysaccharide matrix, carbohydrates, proteins, and signaling molecules [43]. Changes in the structural biofilm conformation of *Candida albicans* exposed to AgNPs were reported [28, 51, 53, 54].

The use of latex plants in the AgNPs green synthesis was proved. *J. curcas* and *L. grandis* extracts produced AgNPs with a size of 47 ± 2.0 nm and 7.6 ± 0.5 nm, respectively. The Fourier transform infrared (FTIR) spectra suggest the incorporation of phenolic OH, amides, amines, and aldehyde in the AgNPs as a stabilizing agent. The smallest AgNPs showed a better effect in plankton and biofilms of *Candida albicans* than the big ones. The AgNPs synthesized proved to be efficient in the inhibition of biofilm formation, changes in morphology and cell lysis

Also, silver nitrate chemical reduction by sodium citrate was evaluated in intermediate and mature *Candida albicans* biofilms. The preformatted biofilms were exposed to 54 μg/mL of AgNPs. After 5 h of exposition, biofilms showed a decrease in the number of viable cells, and

synergism between clove and NPs [49].

**Inhibition test NPs size**

MIC, minimal inhibition concentration. MFC, minimal fungicide concentration.

BIC, biofilm inhibitory concentration.

70% fold increase (combination with antifungal, inhibition zone)

152 Candida Albicans

50% fold increase (combination with antifungal, inhibition zone)

NR, not reported.

**(nm)**

**Table 1.** Biogenic synthesized AgNPs against *Candida albicans.*

when candida albicans was exposed [51].

no differences were found in intermediate or mature biofilm [28].

Due to ZnO low toxicity, ZnO has been used in a medical device such as drug carriers, antibacterial agents, and bioimaging probes, among others. For this reason, the ZnO nanoparticles (ZnONPs) have been used in *Candida albicans* control. The ZnONPs application is reflected by the annual production between 550 and 5500. This is more than 10–100 times higher than any other nanoparticle [60]. As the AgNPs, the ZnONPs characteristics depend on the size, synthesis method, and superficial charge, among others [61]. In order to control these characteristics, the green synthesis method has been used to fabricate ZnONPs with a size, shape, and superficial charge with the desirable characteristic [62, 63].

A promissory ZnONPs application area is their use as antimicrobial. Their effect has been evaluated in soil, plants, bacteria, and fungi [60, 64–66] ZnONPs different synthesis methods in ZnONPs have a big influence in the *Candida albicans* inhibition [68].

The use of *Atalantia monophylla* extracts produced ZnONPs 30 nm that have effect inhibition in *Candida albicans* growth. The author proposed the ZnONPs interaction with the cell wall, penetration to the cell, ion liberation, and the oxidative stress production, triggering the protein, lipid, and DNA oxidation [67].

The microwave aqueous extract from *Suaeda aegyptiaca* produced ZnONPs with a size of 80 nm with a capping produced by metabolites from the plant. The effect of the capping was studied. ZnONPs produced by precipitation method were studied and compared with the plant extract produced. ZnONPs *Suaeda aegyptiaca* produced a major inhibitory effect than the ZnONPs without capping agent, suggesting a synergic effect [68].

Extracts for different plants have been proved to synthesize ZnONPs in order to evaluate the toxicity of the resulting nanoparticles in *Candida albicans* inhibition (**Table 2**).

ZnONPs hybrid has been synthesized using chitosan, gelatin, and polystyrene, among others [75–77].

showed a MIC of 99.7 ± 0.99 μg/mL, whereas the control with zinc acetate showed an MIC of 297.9 ± 2.0 μg/mL. Biofilms exposed to increase the concentration of ZnONPs showed inhibi-

Nanoparticles as New Therapeutic Agents against *Candida albicans*

http://dx.doi.org/10.5772/intechopen.80379

Gelatin was used for the ZnONPs as well. ZnONPs produced with gelatin showed a diameter of 20 nm with a negative superficial charge. The ZnONPs produced were employed to biofilm exposition. ZnONPs in a concentration of 50 μg/mL showed a thickness diminution, resulting

Also, egg albumin was used as a ZnONPs template. The synthesis method produced spherical ZnONPs with a range between 10 and 20 nm. The FITR analysis showed the interaction of egg albumin and ZnONPs. In this work, ZnONPs characterization in the culture media showed importance. The use of 45 μg/ml in Sabouraud's dextrose (SD) nutrient media does not significantly affect ZnONPs stability, size, and integrity. The synthesized ZnONPs showed *Candida albicans* inhibition in a dose-dependent manner. Changes in the *Candida albicans* morphology

ZnONPs were evaluated both alone and as a part of nanocomposites with polystyrene. The use of ZnONPs alone showed *Candida albicans* inhibition. However, when ZnONPs are used in nanocomposites, a major concentration of ZnONPs to inhibit *Candida albicans* is

Nanocomposites with ZnONPs have been produced with different materials in order to increase the growth inhibition of microorganisms [45, 46]. However, the results of the antifungal activity were contradictory; ZnONPs capped by surfactant in cotton fiber have proved the inhibition of *Candida albicans* in 94% [68], while the incorporation of ZnONPs in polylactic

The principal ZnONPs toxicity mechanisms reported are (1) ion liberation, (2) interaction of ZnONPs with the cell wall, and (3) stress oxidative generation [81]. The ion liberation and the interaction of NPs with the cell trigger the generation of oxidative stress; with that the cell lost

Copper exhibits good characteristics such as its antimicrobial activity, chemical stability, and thermal resistance. Due to their toxicity characteristic, copper has been used by Egyptians for water disinfection. The Aztecs used copper to treat sore throats, and the Persian and Indians

Copper has an advantage in comparison with other materials, is cheaper than any other, and is easy to oxidize to copper oxide nanoparticles (CuONPs). The CuONPs can easily make

The CuONPs have recovered importance in the investigation due to their low cost and the variety of applications. CuONPs have been used in the pharmaceutical, medicine, and elec-

nanocomposites with polymers, macromolecules inclusive of other metals [83, 84].

in a weak adherence biofilm compared with the biofilm treated with fluconazole [72].

tion as a result of the ZnONPs concentration [78].

show cavity formation in cells exposed to 15 μg/ml [79].

acid films does not inhibit the *Candida albicans* growth [80].

used it to treat eye infection and venereal ulcers [82].

necessary [77].

their viability [79].

**7.3. Copper oxide nanoparticles**

tronic industries, among others.

Dhillon et al. 2014 [75] used chitosan as a capping and bridge to carry on citric acid, glycerol, starch, and whey powder using the nanospray drying method. The ZnONPs produced have a size range of 93.2–402.5 nm. The smallest ZnONPs were the chitosan starch NPs. Aggregation effect was observed in the largest ZnONPs; this phenomenon could be explained by the superficial charge. However, these ZnONPs have a small effect in *Candida albicans* inhibition.

Collagen was used as a reducing and capping agent. The ZnONPs produced with this method showed a size between 20 and 50 nm negatively charged. ZnONPs coated by collagen

MIC, minimal inhibition concentration.

MFC, minimal fungicide concentration.

NR, not reported.

**Table 2.** Biogenic synthesized ZnONPs against *Candida albicans.*

showed a MIC of 99.7 ± 0.99 μg/mL, whereas the control with zinc acetate showed an MIC of 297.9 ± 2.0 μg/mL. Biofilms exposed to increase the concentration of ZnONPs showed inhibition as a result of the ZnONPs concentration [78].

Gelatin was used for the ZnONPs as well. ZnONPs produced with gelatin showed a diameter of 20 nm with a negative superficial charge. The ZnONPs produced were employed to biofilm exposition. ZnONPs in a concentration of 50 μg/mL showed a thickness diminution, resulting in a weak adherence biofilm compared with the biofilm treated with fluconazole [72].

Also, egg albumin was used as a ZnONPs template. The synthesis method produced spherical ZnONPs with a range between 10 and 20 nm. The FITR analysis showed the interaction of egg albumin and ZnONPs. In this work, ZnONPs characterization in the culture media showed importance. The use of 45 μg/ml in Sabouraud's dextrose (SD) nutrient media does not significantly affect ZnONPs stability, size, and integrity. The synthesized ZnONPs showed *Candida albicans* inhibition in a dose-dependent manner. Changes in the *Candida albicans* morphology show cavity formation in cells exposed to 15 μg/ml [79].

ZnONPs were evaluated both alone and as a part of nanocomposites with polystyrene. The use of ZnONPs alone showed *Candida albicans* inhibition. However, when ZnONPs are used in nanocomposites, a major concentration of ZnONPs to inhibit *Candida albicans* is necessary [77].

Nanocomposites with ZnONPs have been produced with different materials in order to increase the growth inhibition of microorganisms [45, 46]. However, the results of the antifungal activity were contradictory; ZnONPs capped by surfactant in cotton fiber have proved the inhibition of *Candida albicans* in 94% [68], while the incorporation of ZnONPs in polylactic acid films does not inhibit the *Candida albicans* growth [80].

The principal ZnONPs toxicity mechanisms reported are (1) ion liberation, (2) interaction of ZnONPs with the cell wall, and (3) stress oxidative generation [81]. The ion liberation and the interaction of NPs with the cell trigger the generation of oxidative stress; with that the cell lost their viability [79].

#### **7.3. Copper oxide nanoparticles**

ZnONPs hybrid has been synthesized using chitosan, gelatin, and polystyrene, among others

Dhillon et al. 2014 [75] used chitosan as a capping and bridge to carry on citric acid, glycerol, starch, and whey powder using the nanospray drying method. The ZnONPs produced have a size range of 93.2–402.5 nm. The smallest ZnONPs were the chitosan starch NPs. Aggregation effect was observed in the largest ZnONPs; this phenomenon could be explained by the superficial charge. However, these ZnONPs have a small effect in *Candida albicans* inhibition. Collagen was used as a reducing and capping agent. The ZnONPs produced with this method showed a size between 20 and 50 nm negatively charged. ZnONPs coated by collagen

*monophylla*

*pentaphylla*

25 μg/mL (MIC)/50 μg/mL (MFC) 18 *Azadirachta indica* Proteins Elumalai and

*monophylla*

80 μM (MIC)/>2590 μM (MFC) 8 nm *Chelidonium majus* NR Dobrucka et al. 2018

32–40 *Glycosmis*

Strong activity 36 *S. myriocystum* Protein, carbohydrates,

18.01 mm (inhibition zone 100 μg/mL) 80 *Suaeda aegyptiaca* Alcohol, aldehyde,

**(nm)**

80 μM (MIC)/>2590 μM (MFC) 8 *Chelidonium majus* NR Dobrucka et al. 2018

**Synthesis method Capped Reference**

Alkane, C=O stretching, other groups

flavonoids, tannins,

mannitol

and alkane

amine

aromatic group

**Synthesis method Capped Reference**

68.64 *Cassia auriculata* Alkene, alcohol, ether,

10–30 *Vitex trifolia* Proteins, alkanes,

NR Vijayakumar et al.

2018 [67]

Vijayakumar et al., 2018 [70]

Velmurugan 2015

Nagarajan and Kuppusamy 2013

Padalia et al. 2018

Elumalai et al. 2015

Rajabi et al. 2018

[69]

[71]

[72]

[73]

[71]

[68]

2018 [67]

[74]

NR Vijayakumar et al.

[75–77].

154 Candida Albicans

**Inhibition test NPs size**

34 ± 1.28 mm (inhibition zone with

12.5 mm (inhibition zone with

20.3 ± 0.57 mm (inhibition zone with 200 μg/mL)/25 μg/mL (MIC)

**Inhibition test NPs size**

MIC, minimal inhibition concentration. MFC, minimal fungicide concentration.

24 mm (zone inhibition) 30 nm *Atalantia*

**Table 2.** Biogenic synthesized ZnONPs against *Candida albicans.*

100 g/ml)

150 mg/ml)

50 μg/mL (MFC)

NR, not reported.

24 mm (inhibition zone) 30 *Atalantia*

**(nm)**

Copper exhibits good characteristics such as its antimicrobial activity, chemical stability, and thermal resistance. Due to their toxicity characteristic, copper has been used by Egyptians for water disinfection. The Aztecs used copper to treat sore throats, and the Persian and Indians used it to treat eye infection and venereal ulcers [82].

Copper has an advantage in comparison with other materials, is cheaper than any other, and is easy to oxidize to copper oxide nanoparticles (CuONPs). The CuONPs can easily make nanocomposites with polymers, macromolecules inclusive of other metals [83, 84].

The CuONPs have recovered importance in the investigation due to their low cost and the variety of applications. CuONPs have been used in the pharmaceutical, medicine, and electronic industries, among others.

Diverse synthesis methods have been proved to create CuONPs including chemical [85], electrochemical [86], and green synthesis [87].

The synthesis method influences the characteristics as the size, shape, and agglomeration of the CuONPs [88].

CuONP electrochemical production with different solvents and reaction times produces different NPs sizes from 3 to 200 nm. The CuONPs were obtained in water-acetonitrile, with sodium hydroxide as the electrolyte. The CuONPs obtained in these conditions showed a size around 20 nm. The *Candida albicans* exposition to 25 and 50 μg/ml generates a delay in the growth curves. Added to that, 50 μg/ml inhibited completely *Candida albicans* growth [86].

CuONPs prepared by precipitation method coated with acetate were evaluated together with fluconazole. CuONPs coated with acetate were more toxic than CuONPs without coating. CuONPs in combination with fluconazole showed the complete *Candida albicans* inhibition. The fractional inhibitory concentration index (FICI) suggested the additive to moderate synergism between CuONPs and fluconazole [89].

The use of dispersant as ethylene glycol and Tween 80 proved to be efficient in the production of CuONPs capable to the *Candida albicans* growth inhibition. Inhibition with CuONPs was more efficient than the exposition to itraconazole [90]. Also, the effect of CuONPs was evaluated in *Candida albicans* from oral cavities [91], showing that strain isolated from the patients needs until 1000 ppm to generate an inhibitory effect in *Candida albicans*.

**7.4. Other nanoparticles**

15.0 c ± 0.57735 (inhibition zone with 62 μg/mL)/1.93 ± 0.76376 (MIC)

22.5 mm (inhibition zone) Nanostructures

**Table 3.** Biogenic synthesized CuONPs against *Candida albicans*.

~8000

0.15 Log10 growth reduction 22 ± 1 nm Cellulose, chitosan,

amphotericin [110].

NPs has been proved to be effective.

Other metal nanoparticles as gold [AuNPs, [36]], palladium [PdNPs, [91]], and selenium [SeNPs, [92]], among others, have been proven. The microorganisms' elimination by all these

**Inhibition test NPs size (nm) Synthesis method Capped Reference**

10.5 (zone inhibition) 26 ± 4 *Acalypha indica* NR Sivaraj et al.

20 mm (inhibition zone with 50 μg/mL) NR *Sargassum polycystum* NR Vishnu et al.

31.7 Alginate NR El-Batal et al.

Nanoparticles as New Therapeutic Agents against *Candida albicans*

*Viburnum opulus* Cu3

and keratin nanocomposites 2018 [102]

2014 [103]

Ildiz et al. 2017 [104]

2016 [105]

Tram et al., 2017 [106]

(PO4)2

http://dx.doi.org/10.5772/intechopen.80379

Cellulose, chitosan, and keratin

3H2 O

Chemical reduction of palladium salt has produced PdNPs in an average size of 9 nm (±3.9 nm).

SeNPs were prepared by the reduction of selenium chloride inside *K. pneumoniae*. This synthesis produced SeNPs with a size range from 90 to 320 nm. The concentration necessary for growth inhibition of *Candida albicans* was 2000 μg/mL [109]. Another strategy for the *Candida albicans* inhibition induced the SeNPs formation inside of *Lactobacillus* and then used them as an antifungal. This strategy worked with *L. plantarum* and *L. johnsonii. Candida albicans* exposed to both microorganisms becomes more efficient than bacterium without NPs [108]. Schiff base ligand 2-((4,6-dihethoxypyr-imidine-2-yl)methyleneenamino)-6-methoxyphenol has been used in order to capped AuNPs and platinum nanoparticles (PtNPs). Nanoparticles synthetized presented a layer. The NPs showed a granular and spherical shape with size of 38.14 ± 4.5 and 58.64 ± 3.0 nm, respectively. Both nanoparticles showed greater inhibition than

Biogenic PdNP production with watery extract of *Moringa oleifera* flower was evaluated for the *Candida albicans* inhibition. However, these PdNPs had no effect in *Candida albicans* [111]. *Candida albicans* exposition to tellurium NPs produces complete inhibition with of ≥2000 μg/ mL. Besides, the results showed a squalene accumulation and increase in the expression levels

of the ERG1 gene of squalene monooxygenase enzyme [112].

The PdNPs showed a significative *Candida albicans* growth reduction at 150 ppm [107].

CuONPs capped with pyrimidine derivatives have shown a size of 10 nm. The CuONPs showed interaction with DNA and antioxidant activity. However, the CuONPs showed *Candida albicans* inhibition [92].

Nanocomposites with the incorporation of Fe [93] Cd and Ba CuONPs [94], as well as the incorporation of CuONPs into cotton fiber [95, 96], polyurethane [97], polyester [98], copolymer microgel [99], and open polyurethane foams with starch powder [100], have been proved be efficient in the *Candida albicans* growth inhibition.

As in the other nanoparticles, the green synthesis has captured the investigators' attention. Its methodology does not produce toxic subproduct in the nanoparticle production, and it covers the nanoparticles avoiding the agglomeration [31, 84, 87].

Extracts of garlic and ginger have been used for the oxidation of copper. Garlic produces the smallest CuONPs, with a size around 14.62–22.80 nm. However, ginger shows a big quantity of very small nanoparticles. *Candida albicans* has shown major inhibition when exposed to ginger ethanol extract NPs [101]. Few reports about the use of biological extract for the synthesis of CuONPs that inhibited *Candida albicans* were founded (**Table 3**).

Cu2+ ions realized from CuONPs are the principal toxicity mechanisms reported. However, it is not the only one. Some authors reported the CuONP accumulation in the cell wall as well as the oxidative stress increase. However, more studies are necessary in order to understand the NPs toxicity mechanisms.

**Table 3.** Biogenic synthesized CuONPs against *Candida albicans*.

#### **7.4. Other nanoparticles**

Diverse synthesis methods have been proved to create CuONPs including chemical [85], elec-

The synthesis method influences the characteristics as the size, shape, and agglomeration of

CuONP electrochemical production with different solvents and reaction times produces different NPs sizes from 3 to 200 nm. The CuONPs were obtained in water-acetonitrile, with sodium hydroxide as the electrolyte. The CuONPs obtained in these conditions showed a size around 20 nm. The *Candida albicans* exposition to 25 and 50 μg/ml generates a delay in the growth curves. Added to that, 50 μg/ml inhibited completely *Candida albicans* growth [86]. CuONPs prepared by precipitation method coated with acetate were evaluated together with fluconazole. CuONPs coated with acetate were more toxic than CuONPs without coating. CuONPs in combination with fluconazole showed the complete *Candida albicans* inhibition. The fractional inhibitory concentration index (FICI) suggested the additive to moderate syn-

The use of dispersant as ethylene glycol and Tween 80 proved to be efficient in the production of CuONPs capable to the *Candida albicans* growth inhibition. Inhibition with CuONPs was more efficient than the exposition to itraconazole [90]. Also, the effect of CuONPs was evaluated in *Candida albicans* from oral cavities [91], showing that strain isolated from the patients

CuONPs capped with pyrimidine derivatives have shown a size of 10 nm. The CuONPs showed interaction with DNA and antioxidant activity. However, the CuONPs showed

Nanocomposites with the incorporation of Fe [93] Cd and Ba CuONPs [94], as well as the incorporation of CuONPs into cotton fiber [95, 96], polyurethane [97], polyester [98], copolymer microgel [99], and open polyurethane foams with starch powder [100], have been proved

As in the other nanoparticles, the green synthesis has captured the investigators' attention. Its methodology does not produce toxic subproduct in the nanoparticle production, and it covers

Extracts of garlic and ginger have been used for the oxidation of copper. Garlic produces the smallest CuONPs, with a size around 14.62–22.80 nm. However, ginger shows a big quantity of very small nanoparticles. *Candida albicans* has shown major inhibition when exposed to ginger ethanol extract NPs [101]. Few reports about the use of biological extract for the synthesis

Cu2+ ions realized from CuONPs are the principal toxicity mechanisms reported. However, it is not the only one. Some authors reported the CuONP accumulation in the cell wall as well as the oxidative stress increase. However, more studies are necessary in order to understand

needs until 1000 ppm to generate an inhibitory effect in *Candida albicans*.

trochemical [86], and green synthesis [87].

ergism between CuONPs and fluconazole [89].

be efficient in the *Candida albicans* growth inhibition.

the nanoparticles avoiding the agglomeration [31, 84, 87].

of CuONPs that inhibited *Candida albicans* were founded (**Table 3**).

*Candida albicans* inhibition [92].

the NPs toxicity mechanisms.

the CuONPs [88].

156 Candida Albicans

Other metal nanoparticles as gold [AuNPs, [36]], palladium [PdNPs, [91]], and selenium [SeNPs, [92]], among others, have been proven. The microorganisms' elimination by all these NPs has been proved to be effective.

Chemical reduction of palladium salt has produced PdNPs in an average size of 9 nm (±3.9 nm). The PdNPs showed a significative *Candida albicans* growth reduction at 150 ppm [107].

SeNPs were prepared by the reduction of selenium chloride inside *K. pneumoniae*. This synthesis produced SeNPs with a size range from 90 to 320 nm. The concentration necessary for growth inhibition of *Candida albicans* was 2000 μg/mL [109]. Another strategy for the *Candida albicans* inhibition induced the SeNPs formation inside of *Lactobacillus* and then used them as an antifungal. This strategy worked with *L. plantarum* and *L. johnsonii. Candida albicans* exposed to both microorganisms becomes more efficient than bacterium without NPs [108].

Schiff base ligand 2-((4,6-dihethoxypyr-imidine-2-yl)methyleneenamino)-6-methoxyphenol has been used in order to capped AuNPs and platinum nanoparticles (PtNPs). Nanoparticles synthetized presented a layer. The NPs showed a granular and spherical shape with size of 38.14 ± 4.5 and 58.64 ± 3.0 nm, respectively. Both nanoparticles showed greater inhibition than amphotericin [110].

Biogenic PdNP production with watery extract of *Moringa oleifera* flower was evaluated for the *Candida albicans* inhibition. However, these PdNPs had no effect in *Candida albicans* [111].

*Candida albicans* exposition to tellurium NPs produces complete inhibition with of ≥2000 μg/ mL. Besides, the results showed a squalene accumulation and increase in the expression levels of the ERG1 gene of squalene monooxygenase enzyme [112].

#### **7.5. Nanoparticle characteristics and toxicity and** *Candida albicans* **inhibition growth**

The most important NPs characteristics are the size, shape, composition, superficial charge, and hydrodynamic. These characteristics directly influence their capacity to interact with the molecules or cells. Ocsoy et al. (2017) [46] indicate that the size is strictly related to charge density. The smallest of the NPs has the biggest charge density. This explains the big attraction between small NPs and their agglomeration. The NPs agglomeration is a phenomenon that changes their capacity to work as a caring or their toxicokinetic characteristic [33, 107]. In order to improve the distribution and decrease the agglomeration, a surfactant as Pluronic F® has been added to the synthesis process (**Figure 1**). Other surfactants as CTAB, SDS, cation surfactants [113], or PVP have been proved to be efficient [114].

of proteins. The AgNPs size was on average 12.7 nm with a growth inhibition of 64 μg/ mL. Tulsi leaf extract has been used to produce AgNPs with a size of 2–7 nm. The fungicide concentration in the AgNPs produced was of 120 μg/mL [25]. The production of ZnONPs by *Azadirachta indica* [61], *Vitex trifolia* [64], and *Suaeda aegyptiaca* [65], among others (**Table 2**), has been evaluated. The extract produced different ZnONPs sizes and capping (**Table 2**)

Nanoparticles as New Therapeutic Agents against *Candida albicans*

http://dx.doi.org/10.5772/intechopen.80379

Due to the NPs size (nanometer scale), diverse toxicity mechanisms have been proposed (**Figure 2**). One is the direct interaction of the nanoparticle with the cell membrane. The interaction of NPs microorganism is allowed by the NPs superficial charge but also the microorganism superficial charge. This interaction generates disruption of the cell wall and the leakage of ions and the intracellular material with the microorganism's death [117–119].

Consequent to NPs dilution, the ion interaction with the cell is another toxicity mechanism. The ions are incorporated into the cell, and they could interact with thiol groups of proteins and enzymes leading to the inhibition of crucial biological activities [82]. Also, the NPs internalization has been reported; this generates the interaction of NPs and ions with molecules of biological importance as DNA or enzymes [33, 120]. Inside the cell, the NPs or the ions provoke Fenton's type reaction. Due to this, the oxidative stress increases, and the proteins,

**Figure 2.** NPs toxicity mechanisms induced in *Candida albicans*. (1) NPs adhesion in the cell membrane causing disruption in the membrane and death. (2) NPs introduction to the cell with their posterior degradation and ion release. (3) NPs ROS generation outside the cell. (4) NPs and ions ROS generation in interaction with mitochondria. (6) Membrane lipid

peroxidation with nucleus damage. (7) DNA damage by NPS and ions ROS generation.

that influence the growth inhibition.

lipids, and DNA release (**Figure 2**).

Another synthesis methodology that improves these characteristics is the use of subproducts from plants, algae, bacteria, fungi, yeast, etc. [115]. The high content of proteins, reducing sugars or anthocyanins, works as reducing agent; additionally, some of these molecules are adhered in the NPs surface [31]. This addition gives different characteristics to the NPs produced by chemical reduction. The NPs obtained with biogenic methods offer homogeneous NPs with antioxidant characteristics that allow the addition of other molecules and control their toxicity characteristics.

The biogenic NPs production has proven to be efficient inhibiting the *Candida albicans* growth (**Tables 1**–**3**). The differences in the concentration necessary to inhibit their growth are directly related to NPs size, the capping nature, and the microorganisms evaluated [116]. These are evident in the work of Anasane et al. 2016 [52] et al. (2013), where two microorganisms were evaluated in the production of AgNPs, obtaining two NPs sizes. The AgNPs production by the strain SF23 was smaller than that produced by the strain C9. *Candida albicans* presented an MIC of 30 μg/mL with the small AgNPs (size 4–36 nm). Wypij et al. (2017) [37] reported the AgNPs synthesis with *Pilimelia columellifera* subsp. *pallida* SL19, with a capping

**Figure 1.** Scanning electronic microscopy of PdNPs produced by chemical reduction. (A) Without surfactant. (B) With Pluronic F® (5% W/V).

of proteins. The AgNPs size was on average 12.7 nm with a growth inhibition of 64 μg/ mL. Tulsi leaf extract has been used to produce AgNPs with a size of 2–7 nm. The fungicide concentration in the AgNPs produced was of 120 μg/mL [25]. The production of ZnONPs by *Azadirachta indica* [61], *Vitex trifolia* [64], and *Suaeda aegyptiaca* [65], among others (**Table 2**), has been evaluated. The extract produced different ZnONPs sizes and capping (**Table 2**) that influence the growth inhibition.

**7.5. Nanoparticle characteristics and toxicity and** *Candida albicans* **inhibition**

surfactants [113], or PVP have been proved to be efficient [114].

The most important NPs characteristics are the size, shape, composition, superficial charge, and hydrodynamic. These characteristics directly influence their capacity to interact with the molecules or cells. Ocsoy et al. (2017) [46] indicate that the size is strictly related to charge density. The smallest of the NPs has the biggest charge density. This explains the big attraction between small NPs and their agglomeration. The NPs agglomeration is a phenomenon that changes their capacity to work as a caring or their toxicokinetic characteristic [33, 107]. In order to improve the distribution and decrease the agglomeration, a surfactant as Pluronic F® has been added to the synthesis process (**Figure 1**). Other surfactants as CTAB, SDS, cation

Another synthesis methodology that improves these characteristics is the use of subproducts from plants, algae, bacteria, fungi, yeast, etc. [115]. The high content of proteins, reducing sugars or anthocyanins, works as reducing agent; additionally, some of these molecules are adhered in the NPs surface [31]. This addition gives different characteristics to the NPs produced by chemical reduction. The NPs obtained with biogenic methods offer homogeneous NPs with antioxidant characteristics that allow the addition of other molecules and control

The biogenic NPs production has proven to be efficient inhibiting the *Candida albicans* growth (**Tables 1**–**3**). The differences in the concentration necessary to inhibit their growth are directly related to NPs size, the capping nature, and the microorganisms evaluated [116]. These are evident in the work of Anasane et al. 2016 [52] et al. (2013), where two microorganisms were evaluated in the production of AgNPs, obtaining two NPs sizes. The AgNPs production by the strain SF23 was smaller than that produced by the strain C9. *Candida albicans* presented an MIC of 30 μg/mL with the small AgNPs (size 4–36 nm). Wypij et al. (2017) [37] reported the AgNPs synthesis with *Pilimelia columellifera* subsp. *pallida* SL19, with a capping

**Figure 1.** Scanning electronic microscopy of PdNPs produced by chemical reduction. (A) Without surfactant. (B) With

**growth**

158 Candida Albicans

their toxicity characteristics.

Pluronic F® (5% W/V).

Due to the NPs size (nanometer scale), diverse toxicity mechanisms have been proposed (**Figure 2**). One is the direct interaction of the nanoparticle with the cell membrane. The interaction of NPs microorganism is allowed by the NPs superficial charge but also the microorganism superficial charge. This interaction generates disruption of the cell wall and the leakage of ions and the intracellular material with the microorganism's death [117–119].

Consequent to NPs dilution, the ion interaction with the cell is another toxicity mechanism. The ions are incorporated into the cell, and they could interact with thiol groups of proteins and enzymes leading to the inhibition of crucial biological activities [82]. Also, the NPs internalization has been reported; this generates the interaction of NPs and ions with molecules of biological importance as DNA or enzymes [33, 120]. Inside the cell, the NPs or the ions provoke Fenton's type reaction. Due to this, the oxidative stress increases, and the proteins, lipids, and DNA release (**Figure 2**).

**Figure 2.** NPs toxicity mechanisms induced in *Candida albicans*. (1) NPs adhesion in the cell membrane causing disruption in the membrane and death. (2) NPs introduction to the cell with their posterior degradation and ion release. (3) NPs ROS generation outside the cell. (4) NPs and ions ROS generation in interaction with mitochondria. (6) Membrane lipid peroxidation with nucleus damage. (7) DNA damage by NPS and ions ROS generation.

Khan et al*.* (2014) [121] write "when CoFe<sup>2</sup> O4 P NCs gained a higher energy than Eg, the electrons (e− ) of CoFe<sup>2</sup> O4 P NCs were promoted across the band gap to the conduction band (Ec), which creates a hole (h+) in the valence band (Ec). These e− in the EC and holes in the Ev possibly have high reducing and oxidizing powers, respectively." These electron movements generate the NPs reactivity and the oxidative stress generation. The same phenomenon is reported by Setyawati et al. (2014) [122] for TiONPs. These NPs adsorbed UV light, and the adsorbed UV light generates electron excitation, creating a hole in the valence band. The electrons and holes migrate to NPs superficies where they can react with oxygen or water generating oxidative stress. The superficial e− generates the liberation of hydroxyl increasing the mitochondria membrane depolarization and liberation of cytochrome c. Added to this, the results show DNA damage [120]. However, the oxidative stress is not the only mechanisms involved in the AgNPs toxicity; also the membrane fluidity, ergosterol content, and cellular and ultrastructure morphology are altered [123]. The squalene monooxygenase expression in *Candida albicans* exposed to TeNPs showed an increase [112]. The squalene monooxygenase catalyzes the conversion of squalene to 2,3-oxidosqualene; inhibition in this step generates the squalene increase and the disruption of the *Candida albicans* cell wall [107].

**Author details**

**References**

2018.02.028

Hilda Amelia Piñón Castillo<sup>1</sup>

Rigoberto Martínez Chamorro<sup>1</sup>

\*Address all correspondence to<EMAIL_ADDRESS>
2016;**59**:198-219. DOI: 10.1111/myc.12469

DOI: 10.1016/j.jgar.2018.04.012

drudis.2018.01.003

10.1016/j.pdpdt.2018.04.001

Universitario S/N, Campus II, Chihuahua, Chihuahua, México

2 Centro de Investigación en Materiales Avanzados, Chihuahua, México

\*, Laila Nayzzel Muñoz Castellanos<sup>1</sup>

[1] Simon J, Sun HY, Leong HN, Barez MYC, Huang PY, Talwar D, et al. Echinocandins in

[2] Dadar M, Tiwari R, Karthik K, Chakraborty S, Shahali Y, Dhama K. *Candida albicans*— Biology, molecular characterization, pathogenicity, and advances in diagnosis and control—An update. Microbial Pathogenesis. 2018;**117**:128-138. DOI: 10.1016/j.micpath.

[3] Gonçalves SS, Souza ACR, Chowdhary A, Meis JF, Colombo AL. Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus. Mycoses.

[4] de Bedout C, Gómez BL. Candida y candidiasis invasora: Un reto continuo para su diagnóstico temprano. Infection. 2010;**14**:159-171. DOI: 10.1016/S0123-9392(10)70133-8 [5] de Sa NP, de Paula LFJ, Lopes LFF, Cruz LIB, Matos TTS, Lino CI, et al. In vivo and in vitro activity of a bis-arylidenecyclo-alkanone against fluconazole-susceptible and resistant isolates of *Candida albicans*. The Journal of Global Antimicrobial Resistance; 2018.

[6] De la Torre-Saldaña VA, Mayté MV, et al. Factores de riesgo y epidemiología de la candidemia en el Hospital Juárez de México. Medicina Interna de México. 2014;**30**:121-132 [7] El-Baz AF, El-Batal AI, Abomosalam FM, Tayel AA, Shetaia YM, Yang ST. Extracellular biosynthesis of anti-Candida silver nanoparticles using *Monascus purpureus*. Journal of

[8] Salci TP, Negri M, Abadio AKR, Svidzinski TIE, Kioshima ÉS. Targeting Candida spp. to develop antifungal agents. Drug Discovery Today. 2018;**23**:802-814. DOI: 10.1016/j.

[9] Zhou S, Sun Z, Ye Z, Wang Y, Wang L, Xing L, et al. In vitro photodynamic inactivation effects of benzylidene cyclopentanone photosensitizers on clinical fluconazole-resistant *Candida albicans*. Photodiagnosis and Photodynamic Therapy. 2018;**22**:178-186. DOI:

Basic Microbiology. 2016;**56**:531-540. DOI: 10.1002/jobm.201500503

, Reyna Reyes Martínez<sup>1</sup>

1 Facultad de Ciencias Químicas, Universidad Autónoma de Chihuahua, Circuito

invasive candidiasis. Mycoses. 2013;**56**:601-609. DOI: 10.1111/myc.12085

,

Nanoparticles as New Therapeutic Agents against *Candida albicans*

and Erasmo Orrantia Borunda<sup>2</sup>

http://dx.doi.org/10.5772/intechopen.80379

#### **8. Conclusion**

The antibiotic resistance increase in many microorganisms has encouraged researchers to focus their efforts on the synthesis and design of multiple effective compounds in order to combat the resistance mechanism of microorganisms. NPs offer a new and effective "antibiotic" that could work against the resistance mechanism in *Candida albicans*.

The biogenic NPs offer a new generation of NPs that work as a carrier. These NPs offer the possibility to drive the toxicity effect to a specific target, in such way the collateral damage could be diminished.

However, the NPs toxicity mechanisms are not completely understood. The oxidative stress is one of the described mechanisms; it is possible to investigate other mechanisms involving similarity to oxidative stress. More studies are necessary to understand the influence that nanoparticles have in the *Candida albicans* resistance mechanisms and if this exposition could not generate new ones.

#### **Acknowledgements**

This work was partially financed by F-PROMEP-38/REV-04. SEP-23-005 and ECOS NORD 263456.

#### **Conflict of interest**

The authors declare no conflict of interest.

#### **Author details**

Khan et al*.* (2014) [121] write "when CoFe<sup>2</sup>

O4

generating oxidative stress. The superficial e−

(Ec), which creates a hole (h+) in the valence band (Ec). These e−

squalene increase and the disruption of the *Candida albicans* cell wall [107].

otic" that could work against the resistance mechanism in *Candida albicans*.

) of CoFe<sup>2</sup>

electrons (e−

160 Candida Albicans

**8. Conclusion**

could be diminished.

not generate new ones.

**Acknowledgements**

**Conflict of interest**

The authors declare no conflict of interest.

263456.

O4

Ev possibly have high reducing and oxidizing powers, respectively." These electron movements generate the NPs reactivity and the oxidative stress generation. The same phenomenon is reported by Setyawati et al. (2014) [122] for TiONPs. These NPs adsorbed UV light, and the adsorbed UV light generates electron excitation, creating a hole in the valence band. The electrons and holes migrate to NPs superficies where they can react with oxygen or water

the mitochondria membrane depolarization and liberation of cytochrome c. Added to this, the results show DNA damage [120]. However, the oxidative stress is not the only mechanisms involved in the AgNPs toxicity; also the membrane fluidity, ergosterol content, and cellular and ultrastructure morphology are altered [123]. The squalene monooxygenase expression in *Candida albicans* exposed to TeNPs showed an increase [112]. The squalene monooxygenase catalyzes the conversion of squalene to 2,3-oxidosqualene; inhibition in this step generates the

The antibiotic resistance increase in many microorganisms has encouraged researchers to focus their efforts on the synthesis and design of multiple effective compounds in order to combat the resistance mechanism of microorganisms. NPs offer a new and effective "antibi-

The biogenic NPs offer a new generation of NPs that work as a carrier. These NPs offer the possibility to drive the toxicity effect to a specific target, in such way the collateral damage

However, the NPs toxicity mechanisms are not completely understood. The oxidative stress is one of the described mechanisms; it is possible to investigate other mechanisms involving similarity to oxidative stress. More studies are necessary to understand the influence that nanoparticles have in the *Candida albicans* resistance mechanisms and if this exposition could

This work was partially financed by F-PROMEP-38/REV-04. SEP-23-005 and ECOS NORD

P NCs gained a higher energy than Eg, the

generates the liberation of hydroxyl increasing

in the EC and holes in the

P NCs were promoted across the band gap to the conduction band

Hilda Amelia Piñón Castillo<sup>1</sup> \*, Laila Nayzzel Muñoz Castellanos<sup>1</sup> , Rigoberto Martínez Chamorro<sup>1</sup> , Reyna Reyes Martínez<sup>1</sup> and Erasmo Orrantia Borunda<sup>2</sup>

\*Address all correspondence to<EMAIL_ADDRESS>
1 Facultad de Ciencias Químicas, Universidad Autónoma de Chihuahua, Circuito Universitario S/N, Campus II, Chihuahua, Chihuahua, México

2 Centro de Investigación en Materiales Avanzados, Chihuahua, México

#### **References**

[10] Caplan T, Polvi EJ, Xie JL, Buckhalter S, Leach MD, Robbins N, et al. Functional genomic screening reveals core modulators of echinocandin stress responses in *Candida albicans*. Cell Reports. 2018;**23**:2292-2298. DOI: 10.1016/j.celrep.2018.04.084

[25] Ramage G, Vandewalle K, Wickes BL, López-Ribot JL. Characteristics of biofilm formation by *Candida albicans* (xtt). Revista Iberoamericana de Micología. 2001;**18**:163-170 DOI:

Nanoparticles as New Therapeutic Agents against *Candida albicans*

http://dx.doi.org/10.5772/intechopen.80379

[26] Coleman JJ, Okoli I, Tegos GP, Holso EB, Wagner FF, Hamblin MR, et al. Characterization of plant-derived Saponin natural products against *Candida albicans*. ACS Chemical

[27] Monteiro DR, Silva S, Negri M, Gorup LF, de Camargo ER, Oliveira R, et al. Silver colloidal nanoparticles: Effect on matrix composition and structure of *Candida albicans* and *Candida glabrata* biofilms. Journal of Applied Microbiology. 2013;**114**:1175-1183. DOI:

[28] Monteiro DR, Takamiya AS, Feresin LP, Gorup LF, de Camargo ER, Delbem ACB, et al. Susceptibility of *Candida albicans* and *Candida glabrata* biofilms to silver nanoparticles in intermediate and mature development phases. Journal of Prosthodontic Research.

[29] Salari S, Khosravi AR, Mousavi SAA, Nikbakht-Brojeni GH. Mechanisms of resistance to fluconazole in *Candida albicans* clinical isolates from Iranian HIV-infected patients with oropharyngeal candidiasis. The Journal de Mycologie Médicale. 2016;**26**:35-41. DOI:

[30] Maebashi K, Niimi M, Kudoh M, Fischer FJ, Makimura K, Niimi K, et al. Mechanisms of fluconazole resistance in *Candida albicans* isolates from Japanese AIDS patients. The Journal of Antimicrobial Chemotherapy. 2001;**47**:527-536. DOI: 10.1093/jac/47.5.527 [31] Saratale RG, Saratale GD, Shin HS, Jacob JM, Pugazhendhi A, Bhaisare M, et al. New insights on the green synthesis of metallic nanoparticles using plant and waste biomaterials: Current knowledge, their agricultural and environmental applications. Environmental Science and Pollution Research. 2018;**25**:10164-10183. DOI: 10.1007/s11356-017-9912-6 [32] Carpenter AW, Slomberg DL, Rao KS, Schoenfisch MH. Influence of scaffold size on bactericidal activity of nitric oxide-releasing silica nanoparticles. ASC Nano. 2011;**5**:7235-

[33] Carlos A-Q, Blanca S-R, Roco I-R, Amelia P-CH, Lorena M-FS, Alberto D-M, et al. Toxicity effects in pathogen microorganisms exposed to silver nanoparticles. Nanoscience and

[34] Oves M, Aslam M, Rauf MA, Qayyum S, Qari HA, Khan MS, et al. Antimicrobial and anticancer activities of silver nanoparticles synthesized from the root hair extract of Phoenix dactylifera. Materials Science and Engineering: C. 2018;**89**:429-443. DOI:

[35] Aazam ES, Zaheer Z. Growth of Ag-nanoparticles in an aqueous solution and their antimicrobial activities against Gram positive, Gram negative bacterial strains and Candida fungus. Bioprocess and Biosystems Engineering. 2016;**39**:575-584. DOI: 10.1007/

200118163 [pii]

Biology. 2010;**5**:321-332

10.1111/jam.12102

2015;**59**:42-48. DOI: 10.1016/j.jpor.2014.07.004

7244. DOI: 10.1111/j.1743-6109.2008.01122.x.Endothelial

Nanotechnology Letters. 2017;**9**:165-173. DOI: 10.1166/nnl.2017.2275

10.1016/j.mycmed.2015.10.007

10.1016/j.msec.2018.03.035

s00449-016-1539-3

[25] Ramage G, Vandewalle K, Wickes BL, López-Ribot JL. Characteristics of biofilm formation by *Candida albicans* (xtt). Revista Iberoamericana de Micología. 2001;**18**:163-170 DOI: 200118163 [pii]

[10] Caplan T, Polvi EJ, Xie JL, Buckhalter S, Leach MD, Robbins N, et al. Functional genomic screening reveals core modulators of echinocandin stress responses in *Candida albicans*.

[11] Mane A, Vidhate P, Kusro C, Waman V, Saxena V, Kulkarni-Kale U, et al. Molecular mechanisms associated with Fluconazole resistance in clinical *Candida albicans* isolates

[13] Choi J, Kim S-H. A genome tree of life for the fungi kingdom. Proceedings of the National Academy of Sciences of the United States of America. 2017;**114**:201711939. DOI: 10.1073/

[14] Chaffin WL. *Candida albicans* cell wall proteins. Microbiology and Molecular Biology

[15] Gow NAR, Hube B. Importance of the *Candida albicans* cell wall during commensalism and infection. Current Opinion in Microbiology. 2012;**15**:406-412. DOI: 10.1016/j.

[16] Ruiz-Herrera J, Victoria Elorza M, Valentín E, Sentandreu R. Molecular organization of the cell wall of *Candida albicans* and its relation to pathogenicity. FEMS Yeast Research.

[17] Chaffin WL, López-ribot JL, Casanova M, Gozalbo D, Martínez JP, Lo L. Cell wall and secreted proteins of *Candida albicans*: Identification, function, and expression.

[18] Lipke PN, Ovalle R. Cell wall architecture in yeast: New structure and new challenges.

[19] Ramos AP, Desgarennes CP. Artículo de revisión Factores de virulencia en; 2005. pp.

[20] Spreghini E, Davis DA, Subaran R, Kim M, Mitchell AP. Roles of *Candida albicans* Dfg5p and Dcw1p cell surface proteins in growth and hypha formation. Eukaryotic Cell.

[21] Calderone RA, Fonzi WA. Virulence factors of *Candida Albicans*. Trends in Microbiology.

[22] Younes S, Bahnan W, Dimassi HI, Khalaf RA. The *Candida albicans* Hwp2 is necessary for proper adhesion, biofilm formation and oxidative stress tolerance. Microbiological

[23] Kruppa M. Quorum sensing and *Candida albicans*. Mycoses. 2009;**52**:1-10. DOI: 10.1111/j.

[24] Kadosh D, Lopez-Ribot JL. *Candida albicans*: Adapting to succeed. Cell Host & Microbe.

Cell Reports. 2018;**23**:2292-2298. DOI: 10.1016/j.celrep.2018.04.084

from India. Mycoses. 2016;**59**:93-100. DOI: 10.1111/myc.12439 [12] Arenas R. Micología Médica Ilustrada3era edici. McGraw-Hill; 2014

Reviews. 2008;**72**:495-544. DOI: 10.1128/MMBR.00032-07

2006;**6**:14-29. DOI: 10.1111/j.1567-1364.2005.00017.x

Journal of Bacteriology. 1998;**180**:3735-3740

2003;**2**:746-755. DOI: 10.1128/EC.2.4.746-755.2003

2013;**14**:483-485. DOI: 10.1016/j.chom.2013.10.016

Microbiology and Molecular Biology Reviews. 1998;**62**:130-180

Research. 2011;**166**:430-436. DOI: 10.1016/j.micres.2010.08.004

pnas.1711939114

162 Candida Albicans

mib.2012.04.005

12-27

2001;**9**:327-335

1439-0507.2008.01626.x

[36] Shankar PD, Shobana S, Karuppusamy I, Pugazhendhi A, Ramkumar VS, Arvindnarayan S, et al. A review on the biosynthesis of metallic nanoparticles (gold and silver) using bio-components of microalgae: Formation mechanism and applications. Enzyme and Microbial Technology. 2016;**95**:28-44. DOI: 10.1016/j.enzmictec.2016.10.015

antimicrobial activity and reusability. Journal of Molecular Liquids. 2017;**227**:147-152.

Nanoparticles as New Therapeutic Agents against *Candida albicans*

http://dx.doi.org/10.5772/intechopen.80379

[47] Ashajyothi C, Prabhurajeshwar C, Handral HK, Kelmani CR. Investigation of antifungal and anti-mycelium activities using biogenic nanoparticles: An eco-friendly approach. Environmental Nanotechnology, Monitoring and Management. 2016;**5**:81-87. DOI:

[48] Rahisuddin Al-Thabaiti SA, Khan Z, Manzoor N. Biosynthesis of silver nanoparticles and its antibacterial and antifungal activities towards Gram-positive, Gram-negative bacterial strains and different species of Candida fungus. Bioprocess and Biosystems

[49] Parlinska-wojtan M, Depciuch J, Fryc B, Kus-liskiewicz M. Green synthesis and antibacterial effects of aqueous colloidal solutions of silver nanoparticles using clove eugenol.

[50] Padalia H, Moteriya P, Chanda S. Green synthesis of silver nanoparticles from marigold flower and its synergistic antimicrobial potential. Arabian Journal of Chemistry.

[51] Kumar S, Bhattacharya W, Singh M, Halder D, Mitra A. Plant latex capped colloidal silver nanoparticles: A potent anti-biofilm and fungicidal formulation. Journal of Molecular

[52] Anasane N, Golińska P, Wypij M, Rathod D, Dahm H, Rai M. Acidophilic actinobacteria synthesised silver nanoparticles showed remarkable activity against fungi-causing superficial mycoses in humans. Mycoses. 2016;**59**:157-166. DOI: 10.1111/myc.12445

[53] Hamid S, Zainab S, Faryal R, Ali N. Deterrence in metabolic and biofilms forming activity of Candida species by mycogenic silver nanoparticles. Journal of Applied Biomedicine.

[54] Monteiro DR, Silva S, Negri M, Gorup LF, de Camargo ER, Oliveira R, et al. Antifungal activity of silver nanoparticles in combination with nystatin and chlorhexidine digluconate against *Candida albicans* and *Candida glabrata* biofilms. Mycoses. 2013;**56**:672-680.

[55] Lara HH, Romero-Urbina DG, Pierce C, Lopez-Ribot JL, Arellano-Jiménez MJ, Jose-Yacaman M. Effect of silver nanoparticles on *Candida albicans* biofilms: An ultrastructural study. Journal of Nanobiotechnology. 2015;**13**:1-12. DOI: 10.1186/s12951-015-0147-8

[56] Kumar CG, Poornachandra Y. Biodirected synthesis of Miconazole-conjugated bacterial silver nanoparticles and their application as antifungal agents and drug delivery vehicles. Colloids and Surfaces B. 2015;**125**:110-119. DOI: 10.1016/j.colsurfb.2014.11.025

[57] Peña-González CE, Pedziwiatr-Werbicka E, Martín-Pérez T, Szewczyk EM, Copa-Patiño JL, Soliveri J, et al. Antibacterial and antifungal properties of dendronized silver

Engineering. 2015;**38**:1773-1781. DOI: 10.1007/s00449-015-1418-3

2015;**8**:732-741. DOI: 10.1016/j.arabjc.2014.11.015

2017;**15**:249-255. DOI: 10.1016/j.jab.2017.02.003

DOI: 10.1111/myc.12093

Liquids. 2017;**230**:705-713. DOI: 10.1016/j.molliq.2017.01.004

Applied Organometallic Chemistry. 2018;**32**:1-9. DOI: 10.1002/aoc.4276

DOI: 10.1016/j.molliq.2016.12.015

10.1016/j.enmm.2016.04.002

antimicrobial activity and reusability. Journal of Molecular Liquids. 2017;**227**:147-152. DOI: 10.1016/j.molliq.2016.12.015

[47] Ashajyothi C, Prabhurajeshwar C, Handral HK, Kelmani CR. Investigation of antifungal and anti-mycelium activities using biogenic nanoparticles: An eco-friendly approach. Environmental Nanotechnology, Monitoring and Management. 2016;**5**:81-87. DOI: 10.1016/j.enmm.2016.04.002

[36] Shankar PD, Shobana S, Karuppusamy I, Pugazhendhi A, Ramkumar VS, Arvindnarayan S, et al. A review on the biosynthesis of metallic nanoparticles (gold and silver) using bio-components of microalgae: Formation mechanism and applications. Enzyme and

[37] Wypij M, Czarnecka J, Dahm H, Rai M, Golinska P. Silver nanoparticles from Pilimelia columellifera subsp. pallida SL19 strain demonstrated antifungal activity against fungi causing superficial mycoses. Journal of Basic Microbiology. 2017;**57**:793-800. DOI:

[38] Lateef A, Ojo SA, Oladejo SM. Anti-candida, anti-coagulant and thrombolytic activities of biosynthesized silver nanoparticles using cell-free extract of Bacillus safensis LAU 13.

[39] Ghiuță I, Cristea D, Croitoru C, Kost J, Wenkert R, Vyrides I, et al. Characterization and antimicrobial activity of silver nanoparticles, biosynthesized using Bacillus species.

[40] Musa SF, Yeat TS, Kamal LZM, Tabana YM, Ahmed MA, El Ouweini A, et al. Pleurotus sajor-caju can be used to synthesize silver nanoparticles with antifungal activity against *Candida albicans*. Journal of the Science of Food and Agriculture. 2018;**98**:1197-1207. DOI:

[41] Khatoon N, Mishra A, Alam H, Manzoor N, Sardar M. Biosynthesis, characterization, and antifungal activity of the silver nanoparticles against pathogenic candida species.

[42] Moteriya P, Padalia H, Chanda S. Characterization, synergistic antibacterial and free radical scavenging efficacy of silver nanoparticles synthesized using *Cassia roxburghii* leaf extract. Journal, Genetic Engineering & Biotechnology. 2017;**15**:505-513. DOI:

[43] Muthamil S, Devi VA, Balasubramaniam B, Balamurugan K, Pandian SK. Green synthesized silver nanoparticles demonstrating enhanced in vitro and in vivo antibiofilm activity against Candida spp. Journal of Basic Microbiology. 2018;**58**:343-357. DOI: 10.1002/

[44] Kumar P, Senthamil Selvi S, Govindaraju M. Seaweed-mediated biosynthesis of silver nanoparticles using Gracilaria corticata for its antifungal activity against Candida spp.

[45] Khatoon UT, Nageswara Rao GVS, Mohan KM, Ramanaviciene A, Ramanavicius A. Antibacterial and antifungal activity of silver nanospheres synthesized by trisodium citrate assisted chemical approach. Vacuum. 2017;**146**:259-265. DOI: 10.1016/j.

[46] Ocsoy I, Temiz M, Celik C, Altinsoy B, Yilmaz V, Duman F. A green approach for formation of silver nanoparticles on magnetic graphene oxide and highly effective

Applied Nanoscience. 2013;**3**:495-500. DOI: 10.1007/s13204-012-0151-3

Process Biochemistry. 2016;**51**:1406-1412. DOI: 10.1016/j.procbio.2016.06.027

Applied Surface Science. 2018;**438**:66-73. DOI: 10.1016/j.apsusc.2017.09.163

BioNanoScience. 2015;**5**:65-74. DOI: 10.1007/s12668-015-0163-z

Microbial Technology. 2016;**95**:28-44. DOI: 10.1016/j.enzmictec.2016.10.015

10.1002/jobm.201700121

164 Candida Albicans

10.1002/jsfa.8573

10.1016/j.jgeb.2017.06.010

jobm.201700529

vacuum.2017.10.003

and gold nanoparticles with cationic carbosilane dendrons. International Journal of Pharmaceutics. 2017;**528**:55-61. DOI: 10.1016/j.ijpharm.2017.05.067

Synthesis, characterization, and biological properties. Materials Science and Engineering:

Nanoparticles as New Therapeutic Agents against *Candida albicans*

http://dx.doi.org/10.5772/intechopen.80379

[69] Dobrucka R, Dlugaszewska J, Kaczmarek M. Cytotoxic and antimicrobial effects of biosynthesized ZnO nanoparticles using of Chelidonium majus extract. Biomedical

[70] Vijayakumar S, Krishnakumar C, Arulmozhi P, Mahadevan S, Parameswari N. Biosynthesis, characterization and antimicrobial activities of zinc oxide nanoparticles from leaf extract of *Glycosmis pentaphylla* (Retz.) DC. Microbial Pathogenesis. 2018;**116**:44-48. DOI: 10.1016/j.

[71] Elumalai K, Velmurugan S. Green synthesis, characterization and antimicrobial activities of zinc oxide nanoparticles from the leaf extract of *Azadirachta indica* (L.). Applied

[72] Nagarajan S, Kuppusamy KA. Extracellular synthesis of zinc oxide nanoparticle using seaweeds of gulf of Mannar, India. Journal of Nanobiotechnology. 2013;**11**:39. DOI:

[73] Padalia H, Moteriya P, Chanda S. Synergistic antimicrobial and cytotoxic potential of zinc oxide nanoparticles synthesized using *Cassia auriculata* leaf extract. BioNanoScience.

[74] Dobrucka R, Długaszewska J. Biosynthesis and antibacterial activity of ZnO nanoparticles using Trifolium pratense flower extract. Saudi Journal of Biological Sciences.

[75] Dhillon GS, Kaur S, Brar SK. Facile fabrication and characterization of chitosan-based zinc oxide nanoparticles and evaluation of their antimicrobial and antibiofilm activity.

[76] Divya M, Vaseeharan B, Abinaya M, Vijayakumar S, Govindarajan M, Alharbi NS, et al. Biology biopolymer gelatin-coated zinc oxide nanoparticles showed high antibacterial, antibiofilm and anti-angiogenic activity. The Journal of Photochemistry and

Photobiology B: Biology. 2018;**178**:211-218. DOI: 10.1016/j.jphotobiol.2017.11.008

[77] Serkhacheva NS, Yashina NV, Prokopov NI, Gaynanova AA, Kuz'micheva GM, Domoroshchina EN, et al. Bactericidal properties of nanoscale zinc(II) and titanium (IV) oxides of different nature and their nanocomposites with polystyrene. Nanotechnologies in

[78] Vijayakumar S, Vaseeharan B. Antibiofilm, anti cancer and ecotoxicity properties of collagen based ZnO nanoparticles. Advanced Powder Technology. 2018;**29**:2331-2345 [79] Shoeb M, Singh BR, Khan JA, Khan W, Singh BN, Singh HB, et al. ROS-dependent anticandidal activity of zinc oxide nanoparticles synthesized by using egg albumen as a biotemplate. Advances in Natural Sciences: Nanoscience and Nanotechnology. 2013;**4**:1-

International Nano Letters. 2014;**4**:107. DOI: 10.1007/s40089-014-0107-6

Russia. 2016;**11**:99-109. DOI: 10.1134/S1995078016010146

12. DOI: 10.1088/2043-6262/4/3/035015

Surface Science. 2015;**345**:329-336. DOI: 10.1016/j.apsusc.2015.03.176

C. 2017;**78**:1109-1118. DOI: 10.1016/j.msec.2017.03.090

Microdevices. 2018;**20**. DOI: 10.1007/s10544-017-0233-9

micpath.2018.01.003

10.1186/1477-3155-11-39

**2015**:517-523. DOI: 10.1016/j.sjbs.2015.05.016

2018:196-206

Synthesis, characterization, and biological properties. Materials Science and Engineering: C. 2017;**78**:1109-1118. DOI: 10.1016/j.msec.2017.03.090

[69] Dobrucka R, Dlugaszewska J, Kaczmarek M. Cytotoxic and antimicrobial effects of biosynthesized ZnO nanoparticles using of Chelidonium majus extract. Biomedical Microdevices. 2018;**20**. DOI: 10.1007/s10544-017-0233-9

and gold nanoparticles with cationic carbosilane dendrons. International Journal of

[58] Selvaraj M, Pandurangan P, Ramasami N, Rajendran SB, Sangilimuthu SN, Perumal P. Highly potential antifungal activity of quantum-sized silver nanoparticles against *Candida albicans*. Applied Biochemistry and Biotechnology. 2014;**173**:55-66. DOI: 10.1007/

[59] Li D, Liu Z, Yuan Y, Liu Y, Niu F. Green synthesis of gallic acid-coated silver nanoparticles with high antimicrobial activity and low cytotoxicity to normal cells. Process

[60] Rajput VD, Minkina TM, Behal A, Sushkova SN, Mandzhieva S, Singh R, et al. Effects of zinc-oxide nanoparticles on soil, plants, animals and soil organisms: A review.

[61] Mirzaeia Hamed DM. Zinc oxide nanoparticles: Biological synthesis and biomedical applications. Ceramics International. 2013;**43**:1-11. DOI: 10.1016/j.ijnurstu.2008.11.006

[62] Chinnasamy C, Tamilselvam P, Karthick B, Sidharth B, Senthilnathan M. Green synthesis, characterization and optimization studies of zinc oxide nano particles using costusigneus leaf extract. Materials Today: Proceedings. 2018;**5**:6728-6735. DOI: 10.1016/j.

[63] Ahmed S, Chaudhry SA, Ikram S. A review on biogenic synthesis of ZnO nanoparticles using plant extracts and microbes: A prospect towards green chemistry. Journal of Photochemistry and Photobiology B: Biology. 2017;**166**:272-284. DOI: 10.1016/j.

[64] Hou J, Wu Y, Li X, Wei B, Li S, Wang X. Toxic effects of different types of zinc oxide nanoparticles on algae, plants, invertebrates, vertebrates and microorganisms.

[65] Madhumitha G, Elango G, Roopan SM. Biotechnological aspects of ZnO nanoparticles: Overview on synthesis and its applications. Applied Microbiology and Biotechnology.

[66] Ahmed S, Annu SAC, Ikram S. A review on biogenic synthesis of ZnO nanoparticles using plant extracts and microbes: A prospect towards green chemistry. Journal of Photochemistry and Photobiology B: Biology. 2017;**166**:272-284. DOI: 10.1016/j.

[67] Vijayakumar S, Mahadevan S, Arulmozhi P, Sriram S, Praseetha PK. Green synthesis of zinc oxide nanoparticles using *Atalantia monophylla* leaf extracts: Characterization and antimicrobial analysis. Materials Science in Semiconductor Processing. 2018;**82**:39-45.

[68] Rajabi HR, Naghiha R, Kheirizadeh M, Sadatfaraji H, Mirzaei A, Alvand ZM. Microwave assisted extraction as an efficient approach for biosynthesis of zinc oxide nanoparticles:

Chemosphere. 2018;**193**:852-860. DOI: 10.1016/j.chemosphere.2017.11.077

2016;**100**:571-581. DOI: 10.1007/s00253-015-7108-x

Environmental Nanotechnology, Monitoring and Management. 2018;**9**:76-84

Pharmaceutics. 2017;**528**:55-61. DOI: 10.1016/j.ijpharm.2017.05.067

Biochemistry. 2015;**50**:357-366. DOI: 10.1016/j.procbio.2015.01.002

s12010-014-0782-9

166 Candida Albicans

matpr.2017.11.331

jphotobiol.2016.12.011

jphotobiol.2016.12.011

DOI: 10.1016/j.mssp.2018.03.017

[80] Mizielińska M, Łopusiewicz Ł, Mȩżyńska M, Bartkowiak A. The influence of accelerated UV-A and Q-sun irradiation on the antimicrobial properties of coatings containing ZnO nanoparticles. Molecules. 2017;**22**:12-15. DOI: 10.3390/molecules22091556

[93] Pugazhendhi A, Kumar SS, Manikandan M, Saravanan M. Photocatalytic properties and antimicrobial efficacy of Fe doped CuO nanoparticles against the pathogenic bac-

Nanoparticles as New Therapeutic Agents against *Candida albicans*

http://dx.doi.org/10.5772/intechopen.80379

[94] Arunadevi R, Kavitha B, Rajarajan M, Suganthi A, Jeyamurugan A. Investigation of the drastic improvement of photocatalytic degradation of Congo red by monoclinic Cd, Ba-CuO nanoparticles and its antimicrobial activities. Surfaces and Interfaces.

[95] Eremenko AM, Petrik IS, Smirnova NP, Rudenko AV, Marikvas YS. Antibacterial and antimycotic activity of cotton fabrics, impregnated with silver and binary silver/copper nanoparticles. Nanoscale Research Letters. 2016;**11**:1-9. DOI: 10.1186/

[96] El-nahhal IM, Elmanama AA, Amara N, Qodih FS, Selmane M, Chehimi MM. The efficacy of surfactants in stabilizing coating of nano-structured CuO particles onto the surface of cotton fibers and their antimicrobial activity. Materials Chemistry and Physics.

[97] Savelyev Y, Gonchar A, Movchan B, Gornostay A, Vozianov S, Rudenko A, et al. Antibacterial polyurethane materials with silver and copper nanoparticles. Materials

[98] Ballo MKS, Rtimi S, Kiwi J, Pulgarin C, Entenza JM, Bizzini A. Fungicidal activity of copper-sputtered flexible surfaces under dark and actinic light against azole-resistant *Candida albicans* and *Candida glabrata*. Journal of Photochemistry and Photobiology B:

[99] Khan J, Siddiq M, Akram B, Ashraf MA. In-situ synthesis of CuO nanoparticles in P(NIPAM-co-AAA) microgel, structural characterization, catalytic and biological applications. Arabian Journal of Chemistry. 2018;**11**:897-909. DOI: 10.1016/j.arabjc.

[100] Reza H, Saeed M, Dorraji S, Fakhrzadeh V, Eslami H. Starch-based polyurethane/CuO nanocomposite foam: Antibacterial effects for infection control. International Journal of

[101] El AA, Gehan R, Ayman AG, El Khateeb Y, Hassaan MM. Eco-friendly synthesis of metal nanoparticles using ginger and garlic extracts as biocompatible novel antioxidant and antimicrobial agents. Journal of Nanostructure in Chemistry. 2018;**8**:71-81. DOI:

[102] El-Batal AI, Al-Hazmi NE, Mosallam FM, El-Sayyad GS. Biogenic synthesis of copper nanoparticles by natural polysaccharides and *Pleurotus ostreatus* fermented fenugreek using gamma rays with antioxidant and antimicrobial potential towards some wound pathogens. Microbial Pathogenesis. 2018;**118**:159-169. DOI: 10.1016/j.micpath.2018.

Today: Proceedings. 2017;**4**:87-94. DOI: 10.1016/j.matpr.2017.01.196

Biology. 2017;**174**:229-234. DOI: 10.1016/j.jphotobiol.2017.07.030

Biological Macromolecules. 2018;**111**:1076-1082

teria and fungi. Microbial Pathogenesis. 2018;**122**:84-89

2018;**10**:32-44. DOI: 10.1016/j.surfin.2017.11.004

s11671-016-1240-0

2018;**215**:221-228

2017.12.018

03.013

10.1007/s40097-018-0255-8

[93] Pugazhendhi A, Kumar SS, Manikandan M, Saravanan M. Photocatalytic properties and antimicrobial efficacy of Fe doped CuO nanoparticles against the pathogenic bacteria and fungi. Microbial Pathogenesis. 2018;**122**:84-89

[80] Mizielińska M, Łopusiewicz Ł, Mȩżyńska M, Bartkowiak A. The influence of accelerated UV-A and Q-sun irradiation on the antimicrobial properties of coatings containing ZnO

[81] Agarwal H, Menon S, Venkat Kumar S, Rajeshkumar S. Mechanistic study on antibacterial action of zinc oxide nanoparticles synthesized using green route. Chemico-Biological

[82] Longano D, Ditaranto N, Sabbatini L, Torsi L. In: Nicola Coffi MR, editor. Nano Anti-

[83] Ingle AP, Duran N, Rai M. Bioactivity, mechanism of action, and cytotoxicity of copper-based nanoparticles: A review. Applied Microbiology and Biotechnology. 2014;**98**:1001-1009.

[84] Natan M, Banin E. From Nano to Micro: Using nanotechnology to combat microorganisms and their multidrug resistance. FEMS Microbiology Reviews. 2017;**41**:302-322. DOI:

[85] Bogdanovic U, Lazic V, Vodnik V, Budimir M, Markovic Z, Dimitrijevic S. Copper nanoparticles with high antimicrobial activity. Materials Letters. 2014;**128**:75-78. DOI:

[86] Katwal R, Kaur H, Sharma G, Naushad M, Pathania D. Electrochemical synthesized copper oxide nanoparticles for enhanced photocatalytic and antimicrobial activity. Journal

[87] Din MI, Arshad F, Hussain Z, Mukhtar M. Green adeptness in the synthesis and stabilization of copper nanoparticles: Catalytic, antibacterial, cytotoxicity, and antioxidant activities. Nanoscale Research Letters. 2017;**12**:638. DOI: 10.1186/s11671-017-2399-8 [88] Tamayo L, Azócar M, Kogan M, Riveros A, Páez M. Copper-polymer nanocomposites: An excellent and cost-effective biocide for use on antibacterial surfaces. Materials Science

[89] Weitz IS, Maoz M, Panitz D, Eichler S, Segal E. Combination of CuO nanoparticles and fluconazole: Preparation, characterization, and antifungal activity against *Candida albi-*

*cans*. Journal of Nanoparticle Research. 2015;**17**. DOI: 10.1007/s11051-015-3149-4 [90] Ramyadevi J, Jeyasubramanian K, Marikani A, Rajakumar G, Rahuman AA. Synthesis and antimicrobial activity of copper nanoparticles. Materials Letters. 2012;**71**:114-116.

[91] Amiri M, Etemadifar Z, Daneshkazemi A, Nateghi M. Antimicrobial effect of copper oxide nanoparticles on some oral bacteria and candida species. Journal of Dental